



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> C12N 15/53, 15/11, 9/02 , C12Q 1/68, A01H 5/00	<b>A1</b>	<b>(11) International Publication Number:</b> WO 93/20206 <b>(43) International Publication Date:</b> 14 October 1993 (14.10.93)
<b>(21) International Application Number:</b> PCT/AU93/00127 <b>(22) International Filing Date:</b> 25 March 1993 (25.03.93)  <b>(30) Priority data:</b> PL 1538 27 March 1992 (27.03.92) AU PL 6698 7 January 1993 (07.01.93) AU  <b>(71) Applicant (for all designated States except US):</b> INTERNATIONAL FLOWER DEVELOPMENTS PTY. LTD. [AU/AU]; 16 Gipps Street, Collingwood, VIC 3066 (AU).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> HOLTON, Timothy, Albert [AU/AU]; Unit 1, 19 Oldis Avenue, Northcote, VIC 3070 (AU). CORNISH, Edwina, Cecily [AU/AU]; Lot 33, Leadbetter Road, Upper Beaconsfield, VIC 3808 (AU). TANAKA, Yoshikazu [JP/AU]; 5/49 Bellevue Avenue, Rosanna, VIC 3084 (AU).		<b>(74) Agents:</b> SLATTERY, John, M. et al.; Davies Collison Cave, 1 Little Collins St., Melbourne, VIC 3000 (AU).  <b>(81) Designated States:</b> AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> GENETIC SEQUENCES ENCODING FLAVONOID PATHWAY ENZYMES AND USES THEREFOR		
<b>(57) Abstract</b>		
<p>The present invention relates to a nucleic acid isolate comprising a sequence of nucleotides encoding, or complementary to a sequence encoding, a flavonoid 3'-hydroxylase or a functional derivative thereof. The present invention also relates to transgenic plants carrying and/or expressing the above-mentioned nucleic acid material.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

**GENETIC SEQUENCES ENCODING FLAVONOID PATHWAY  
ENZYMES AND USES THEREFOR**

- 5 The present invention relates generally to genetic sequences encoding flavonoid pathway metabolising enzymes and more particularly to flavonoid 3'-hydroxylase or fragments or derivatives thereof and their use in the manipulation of pigmentation in plants and other organisms.
- 10 The flower industry strives to develop new and different varieties of flowering plants. An effective way to create such novel varieties is through the manipulation of flower colour. Classical breeding techniques have been used with some success to produce a wide range of colours for most of the commercial varieties of flowers. This approach has been limited, however, by the constraints of a particular species' gene
- 15 pool and for this reason it is rare for a single species to have a full spectrum of coloured varieties. In addition, traditional breeding techniques lack precision. The aesthetic appeal of the flower is a combination of many factors such as form, scent and colour; modification of one character through hybridization can often be at the expense of an equally valuable feature. The ability to engineer precise colour
- 20 changes in cutflower and ornamental species would offer significant commercial opportunities in an industry which has rapid product turnover and where novelty is an important market characteristic.

Flower colour is predominantly due to two types of pigment: flavonoids and

25 carotenoids. Flavonoids contribute to a range of colours from yellow to red to blue. Carotenoids impart an orange or yellow tinge and are commonly the major pigment in yellow or orange flowers. The flavonoid molecules which make the major contribution to flower colour are the anthocyanins which are glycosylated derivatives of cyanidin, delphinidin, petunidin, peonidin, malvidin and pelargonidin, and are

30 localised in the vacuole. The different anthocyanins can produce marked differences in colour. Flower colour is also influenced by co-pigmentation with colourless flavonoids, metal complexation, glycosylation, acylation and vacuolar pH (Forkmann,

1991).

The biosynthetic pathway for the flavonoid pigments (hereinafter referred to as the "flavonoid pathway") is well established and is shown in Figure 1 (Ebel and  
5 Hahlbrock, 1988; Hahlbrock and Grisebach, 1979; Wiering and De Vlaming, 1984; Schram *et al.*, 1984; Stafford, 1990). The first committed step in the pathway involves the condensation of three molecules of malonyl-CoA with one molecule of *p*-coumaroyl-CoA. This reaction is catalysed by the enzyme chalcone synthase (CHS). The product of this reaction, 2',4,4',6', tetrahydroxy-chalcone, is normally  
10 rapidly isomerized to produce naringenin by the enzyme chalcone flavanone isomerase (CHI). Naringenin is subsequently hydroxylated at the 3 position of the central ring by flavanone 3-hydroxylase (F3H) to produce dihydrokaempferol (DHK).

The pattern of hydroxylation of the B-ring of DHK plays a key role in determining  
15 petal colour. The B-ring can be hydroxylated at either the 3', or both the 3' and 5' positions, to produce dihydroquercetin (DHQ) and dihydromyricetin (DHM), respectively. Two key enzymes involved in this pathway are flavonoid 3'-hydroxylase and flavonoid 3',5'-hydroxylase, both of the cytochrome P450 class. Cytochrome P450 enzymes are widespread in nature and genes have been isolated and sequenced from  
20 vertebrates, insects, yeasts, fungi, bacteria and plants.

Flavonoid 3'-hydroxylase acts on DHK to produce DHQ and on naringenin to produce eriodictyol. Reduction and glycosylation of DHQ produces the cyanidin-glycoside and peonidin-glycoside pigments which, in many plant species (for example  
25 rose, carnation and chrysanthemum), contribute to red and pink flower colour. The synthesis of these anthocyanins can also result in other flower colours. For example, blue cornflowers contain cyanin. The ability to control flavonoid 3'-hydroxylase activity, or other enzymes involved in the flavonoid pathway, in flowering plants would provide a means to manipulate petal colour. Different coloured versions of  
30 a single cultivar could thereby be generated and in some instances a single species would be able to produce a broader spectrum of colours.

In accordance with the present invention, the genetic sequences encoding flavonoid 3'-hydroxylase have been identified and cloned. These recombinant sequences permit the modulation of hydroxylation of substrates such as DHK and naringenin, leading to a modification of anthocyanin composition, thereby providing a means to  
5 manipulate petal colour. The presence of the flavonoid 3'-hydroxylase would allow the diversion of the metabolic pathway from DHK to anthocyanin derivatives of anthocyanidins such as cyanidin and peonidin, thereby providing a means to manipulate petal colour by modulation of the level of 3'-hydroxylation. Accordingly, the present invention relates to the altering of flavonoid 3'-hydroxylase activity in  
10 plants, which encompasses elevating or reducing levels of existing flavonoid 3'-hydroxylase activity by introducing the sequences of the present invention. Reduction in levels of flavonoid 3'-hydroxylase activity may also be referred to as down-regulation. Moreover, the present invention extends beyond flowers to fruit and vegetable plants and to leaves of, for example, ornamental plants.

15

Accordingly, one aspect of the present invention provides a nucleic acid isolate comprising a sequence of nucleotides encoding, or complementary to a sequence encoding, flavonoid 3'-hydroxylase enzyme (hereinafter referred to as 3'-hydroxylase) or a functional derivative of the enzyme.

20

By the term "nucleic acid isolate" is meant a genetic sequence in a non-naturally-occurring condition. Generally, this means isolated away from its natural state or synthesized or derived in a non-naturally-occurring environment. More specifically, it includes nucleic acid molecules formed or maintained *in vitro*, including genomic  
25 DNA fragments, recombinant or synthetic molecules and nucleic acids in combination with heterologous nucleic acids. It also extends to the genomic DNA or cDNA or part thereof encoding 3'-hydroxylase or part thereof in reverse orientation relative to its or another promoter. It further extends to naturally-occurring sequences following at least a partial purification relative to other nucleic  
30 acid sequences.

The term "genetic sequences" is used herein in its most general sense and encompasses any contiguous series of nucleotide bases specifying directly, or via a complementary series of bases, a sequence of amino acids in a 3'-hydroxylase. Such  
5 a sequence of amino acids may constitute a full-length 3'-hydroxylase or an active truncated form thereof or may correspond to a particular region such as an N-terminal, C-terminal or internal portion of the enzyme. The nucleic acid sequences contemplated herein also encompass oligonucleotides useful as genetic probes or as  
10 "antisense" molecules capable of regulating expression of the corresponding gene in a plant. An "antisense molecule" as used herein may also encompass a gene construct comprising the structural genomic or cDNA gene or part thereof in reverse orientation relative to its or another promoter.

In one embodiment the nucleic acid sequence encoding 3'-hydroxylase or various  
15 functional derivatives thereof are used to reduce the activity of an endogenous 3'-hydroxylase, or alternatively the nucleic acid sequence encoding this enzyme or various derivatives or parts thereof are used in the antisense orientation to reduce activity of the 3'-hydroxylase. Although not wishing to limit the present invention to any one theory, it is possible that an antisense 3'-hydroxylase transcript or fragment  
20 or part thereof (for example, an oligonucleotide molecule) would form a duplex with all or part of the naturally occurring mRNA specified for the enzyme thus preventing accumulation of or translation from the mRNA into active enzyme. In a further alternative, ribozymes could be used to inactivate target nucleic acid sequences.

25 Reference herein to the altering of flavonoid 3'-hydroxylase activity relates to an elevation or reduction in activity of up to 30% or more preferably of 30-50%, or even more preferably 50-75% or still more preferably 75% or greater above or below the normal endogenous or existing levels of activity. The level of activity can be readily assayed using a modified version of the method described by Stotz and  
30 Forkmann (1982) (see Example 1).

The nucleic acids of the present invention may be a ribonucleic acid or deoxyribonucleic acids, single or double stranded and linear or covalently closed circular molecules. Preferably, the nucleic acid molecule is cDNA. The present invention also extends to other nucleic acid molecules which hybridize under low, preferably under medium and most preferably under high stringency conditions with the nucleic acid molecules of the present invention and in particular to the sequence of nucleotides set forth in Figure 5 or a part or region thereof. In its most preferred embodiment, the present invention extends to a nucleic acid molecule having a nucleotide sequence set forth in Figure 5 or to a molecule having at least 40%, more preferably at least 45%, even more preferably at least 55%, still more preferably at least 65-70%, and yet even more preferably greater than 85% similarity at the level of nucleotide or amino acid sequence to at least one or more regions of the sequence set forth in Figure 5 and wherein the nucleic acid encodes or is complementary to a sequence which encodes an enzyme having 3'-hydroxylase activity. It should be noted, however, that nucleotide or amino acid sequences may have similarities below the above given percentages and yet still encode 3'-hydroxylase activity and such molecules may still be considered in the scope of the present invention where they have regions of sequence conservation. The present invention further extends to nucleic acid molecules in the form of oligonucleotide primers or probes capable of hybridizing to a portion of the nucleic acid molecules contemplated above, and in particular those set forth in Figure 5, under low, preferably under medium and most preferably under high stringency conditions. Preferably the portion corresponds to the 5' or the 3' end of the gene. For convenience the 5' end is considered herein to define a region substantially between the start codon of the structural genetic sequence to a centre portion of the gene, and the 3' end is considered herein to define a region substantially between the centre portion of the gene and the terminating codon of the structural genetic sequence. It is clear, therefore, that oligonucleotides or probes may hybridize to the 5' end or the 3' end or to a region common to both the 5' and the 3' ends. The present invention extends to all such probes. Preferred oligonucleotides are set forth in Example 1.



The nucleic acid or its complementary form may encode the full-length enzyme or a part or derivative thereof. By "derivative" is meant any single or multiple amino acid substitutions, deletions, and/or additions relative to the naturally-occurring enzyme and which retains 3'-hydroxylase activity. In this regard, the nucleic acid includes the naturally-occurring nucleotide sequence encoding 3'-hydroxylase or may contain single or multiple nucleotide substitutions, deletions and/or additions to said naturally-occurring sequence. The nucleic acid of the present invention or its complementary form may also encode a "part" of the 3'-hydroxylase, whether active or inactive, and such a nucleic acid molecule may be useful as an oligonucleotide probe, primer for polymerase chain reactions or in various mutagenic techniques, or for the generation of antisense molecules.

Amino acid insertional derivatives of the 3'-hydroxylase of the present invention include amino and/or carboxyl terminal fusions as well as intra-sequence insertions of single or multiple amino acids. Insertional amino acid sequence variants are those in which one or more amino acid residues are introduced into a predetermined site in the protein although random insertion is also possible with suitable screening of the resulting product. Deletional variants are characterised by the removal of one or more amino acids from the sequence. Substitutional amino acid variants are those in which at least one residue in the sequence has been removed and a different residue inserted in its place. Typical substitutions are those made in accordance with Table 1 overleaf.

Where the 3'-hydroxylase is derivatised by amino acid substitution, the amino acids are generally replaced by other amino acids having like properties, such as hydrophobicity, hydrophilicity, electronegativity, bulky side chains and the like. Amino acid substitutions are typically of single residues. Amino acid insertions will usually be in the order of about 1-10 amino acid residues and deletions will range from about 1-20 residues. Preferably, deletions or insertions are made in adjacent pairs, i.e. a deletion of two residues or insertion of two residues.



The amino acid variants referred to above may readily be made using peptide synthetic techniques well known in the art, such as solid phase peptide synthesis (Merrifield, 1964) and the like, or by recombinant DNA manipulations. Techniques for making substitution mutations at predetermined sites in DNA having known or partially known sequence are well known and include, for example, M13 mutagenesis. The manipulation of DNA sequence to produce variant proteins which manifest as substitutional, insertional or deletional variants are conveniently described, for example, in Sambrook *et al.* (1989).

10

TABLE 1

Suitable residues for amino acid substitutions

	<u>Original Residue</u>	<u>Exemplary Substitutions</u>
	Ala	Ser
15	Arg	Lys
	Asn	Gln; His
	Asp	Glu
	Cys	Ser
	Gln	Asn
20	Glu	Asp
	Gly	Pro
	His	Asn; Gln
	Ile	Leu; Val
	Leu	Ile; Val
25	Lys	Arg; Gln; Glu
	Met	Leu; Ile
	Phe	Met; Leu; Tyr
	Ser	Thr
	Thr	Ser
30	Trp	Tyr
	Tyr	Trp; Phe
	Val	Ile; Leu

SUBSTITUTE SHEET

Other examples of recombinant or synthetic mutants and derivatives of the 3'-hydroxylase of the present invention include single or multiple substitutions, deletions and/or additions of any molecule associated with the enzyme such as carbohydrates,  
5 lipids and/or proteins or polypeptides.

The terms "analogues" and "derivatives" also extend to any functional chemical equivalent of the 3'-hydroxylase and also to any amino acid derivative described above. For convenience, reference to "3'-hydroxylase" herein includes reference to  
10 any mutants, derivatives, analogues, homologues or fragments thereof.

The present invention is exemplified using nucleic acid sequences derived from petunia since this represents the most convenient and preferred source of material to date. However, one skilled in the art will immediately appreciate that similar  
15 sequences can be isolated from any number of sources such as other plants or certain microorganisms. Examples of other plants include, but are not limited to, carnation, chrysanthemum, rose, maize, snapdragon, tobacco, cornflower, pelargonium and morning glory. All such nucleic acid sequences encoding directly or indirectly a flavonoid pathway enzyme and in particular 3'-hydroxylase, regardless of their source,  
20 are encompassed by the present invention.

The nucleic acid molecules contemplated herein may exist in either orientation alone or in combination with a vector molecule, for example an expression-vector. The term vector molecule is used in its broadest sense to include any intermediate vehicle  
25 for the nucleic acid molecule, capable of facilitating transfer of the nucleic acid into the plant cell and/or facilitating integration into the plant genome. An intermediate vehicle may, for example, be adapted for use in electroporation, microprojectile bombardment, *Agrobacterium*-mediated transfer or insertion via DNA or RNA viruses. The intermediate vehicle and/or the nucleic acid molecule contained  
30 therein may or may not need to be stably integrated into the plant genome. Such vector molecules may also replicate and/or express in prokaryotic cells. Preferably, the vector molecules or parts thereof are capable of integration into the plant

genome. The nucleic acid molecule may additionally contain a promoter sequence capable of directing expression of the nucleic acid molecule in a plant cell. The nucleic acid molecule and promoter may also be introduced into the cell by any number of means such as those described above.

5

In accordance with the present invention, a nucleic acid sequence encoding 3'-hydroxylase or a derivative or part thereof may be introduced into and expressed in a plant in either orientation thereby providing a means either to convert DHK and/or other suitable substrates, if synthesised in the plant cell, ultimately into  
10 anthocyanin derivatives of anthocyanidins such as cyanidin and/or peonidin, or alternatively to inhibit such conversion of metabolites by reducing or eliminating endogenous or existing 3'-hydroxylase activity. The production of anthocyanins contributes to the production of a red or blue flower colour. Expression of the nucleic acid sequence in either orientation in the plant may be constitutive, inducible  
15 or developmental, and may also be tissue-specific. The word expression is used in its broadest sense to include production of RNA or of both RNA and protein. It also extends to partial expression of a nucleic acid molecule.

According to this aspect of the present invention there is provided a method for  
20 producing a transgenic plant capable of synthesizing 3'-hydroxylase or active mutants or derivatives thereof, said method comprising stably transforming a cell of a suitable plant with a nucleic acid molecule which comprises a sequence of nucleotides encoding said 3'-hydroxylase, under conditions permitting the eventual expression of said nucleic acid molecule, regenerating a transgenic plant from the cell and growing  
25 said transgenic plant for a time and under conditions sufficient to permit the expression of the nucleic acid. The transgenic plant may thereby produce elevated levels of 3'-hydroxylase activity relative to the amount expressed in a comparable non-transgenic plant.

Another aspect of the present invention contemplates a method for producing a transgenic plant with reduced endogenous or existing 3'-hydroxylase activity, said method comprising stably transforming a cell of a suitable plant with a nucleic acid molecule which comprises a sequence of nucleotides encoding or complementary to a sequence encoding 3'-hydroxylase, regenerating a transgenic plant from the cell and where necessary growing said transgenic plant under conditions sufficient to permit the expression of the nucleic acid.

10 Yet another aspect of the present invention contemplates a method for producing a genetically modified plant with reduced endogenous or existing 3'-hydroxylase activity, said method comprising altering the 3'-hydroxylase gene through modification of the endogenous sequences via homologous recombination from an appropriately altered 3'-hydroxylase gene or derivative or part thereof introduced  
15 into the plant cell, and regenerating the genetically modified plant from the cell.

In a preferred embodiment, the present invention contemplates a method for producing a transgenic flowering plant exhibiting altered inflorescence properties, said method comprising stably transforming a cell of a suitable plant with a nucleic acid sequence of the present invention, regenerating a transgenic plant from the cell and growing said transgenic plant for a time and under conditions sufficient to permit the expression of the nucleic acid sequence into the 3'-hydroxylase enzyme. Alternatively, said method may comprise stably transforming a cell of a suitable plant with a nucleic acid sequence of the present invention or its complementary sequence,  
25 regenerating a transgenic plant from the cell and growing said transgenic plant for a time and under conditions sufficient to alter the level of activity of the endogenous or existing 3'-hydroxylase. Preferably the altered level would be less than the endogenous or existing level of 3'-hydroxylase activity in a comparable non-transgenic plant. Without wishing to limit the present invention, one theory of mode of action  
30 is that reduction of the endogenous 3'-hydroxylase activity requires the expression of the introduced nucleic acid sequence or its complementary sequence. However, expression of the introduced genetic sequence or its complement may not be

required to achieve the desired effect: namely, a flowering plant exhibiting altered inflorescence properties.

5 In a related embodiment, the present invention contemplates a method for producing a flowering plant exhibiting altered inflorescence properties, said method comprising alteration of the 3'-hydroxylase gene through modification of the endogenous sequences via homologous recombination from an appropriately altered 3'-hydroxylase gene or derivative or part thereof introduced into the plant cell, and regenerating the genetically modified plant from the cell.

10

The nucleic acid molecule of the present invention may or may not be developmentally regulated. Preferably, the altered inflorescence includes the production of red flowers or other colour shades depending on the physiological conditions of the recipient plant. By "recipient plant" is meant a plant capable of  
15 producing a substrate for the 3'-hydroxylase enzyme, or producing the 3'-hydroxylase enzyme itself, and possessing the appropriate physiological properties and genotype required for the development of the colour desired. This may include but is not limited to petunia, carnation, chrysanthemum, rose, snapdragon, tobacco, cornflower, pelargonium, lisianthus and morning glory.

20

Accordingly, the present invention extends to a method for producing a transgenic plant capable of expressing a recombinant gene encoding 3'-hydroxylase or part thereof or which carries a nucleic acid sequence which is substantially complementary to all or a part of a mRNA molecule optionally transcribable where  
25 required to effect regulation of a 3'-hydroxylase, said method comprising stably transforming a cell of a suitable plant with the nucleic acid isolate comprising a sequence of nucleotides encoding, or complementary to a sequence encoding, 3'-hydroxylase or a derivative or part thereof, where necessary under conditions permitting the eventual expression of said nucleic acid isolate, and regenerating a  
30 transgenic plant from the cell.

One skilled in the art will immediately recognise the variations applicable to the methods of the present invention, such as increasing or decreasing the expression of the enzyme naturally present in a target plant leading to differing shades of colours  
5 such as different shades of red.

The present invention, therefore, extends to all transgenic plants containing all or part of the nucleic acid sequence of the present invention and/or any homologues or related forms thereof or antisense forms of any of these and in particular those  
10 transgenic plants which exhibit altered inflorescence properties. The transgenic plants may contain an introduced nucleic acid molecule comprising a nucleotide sequence encoding or complementary to a sequence encoding 3'-hydroxylase. Generally the nucleic acid would be stably introduced into the plant genome, although the present invention also extends to the introduction of the 3'-hydroxylase  
15 nucleotide sequence within an autonomously-replicating nucleic acid sequence such as a DNA or RNA virus capable of replicating within the plant cell. The invention also extends to seeds from such transgenic plants. Such seeds, especially if coloured, will be useful as proprietary tags for plants.

20 A further aspect of the present invention is directed to recombinant forms of 3'-hydroxylase. The recombinant forms of the enzymes will provide a source of material for research to develop, for example, more active enzymes and may be useful in developing *in vitro* systems for production of coloured compounds.

25 Still a further aspect of the present invention contemplates the use of the genetic sequences described herein in the manufacture of a genetic construct capable of expressing a 3'-hydroxylase enzyme or down-regulating an endogenous 3'-hydroxylase in a plant.

30 The present invention is further described by reference to the following non-limiting Figures and Example.

In the Figures:

Figures 1 is a schematic representation of the biosynthesis pathway for the flavonoid pigments. Enzymes involved in the first part of the pathway have been indicated as follows: PAL = Phenylalanine ammonia-lyase; C4H = Cinnamate 4-hydroxylase; 4CL = 4-coumarate: CoA ligase; CHS = Chalcone synthase; CHI = Chalcone flavanone isomerase; F3H = Flavanone 3-hydroxylase; DFR = Dihydroflavonol-4-reductase; UFGT = UDP-glucose: flavonoid-3-O-glucosyl-transferase. The later steps correspond to conversions that occur in *P. hybrida* flowers and include: 1 = addition of a rhamnose sugar to the glucosyl residue of cyanidin-3-glucoside and delphinidin-3-glucoside; 2 = acylation and 5-O-glucosylation; 3 = 3' methylation; 4 = 5' methylation; 5 = 3',5' methylation.

Figure 2(A) is a schematic representation of DNA fragments used to probe cDNA library #1 to identify cytochrome P450 homologues. P450: generalized cytochrome P450 cDNA clone with the haem-binding domain (Haem) indicated by the shaded box; pCGP142: a 980 bp fragment was obtained by PCR with oligos 1 and 2 using pCGP142 DNA as template; pCGP147: a 1.3 kb fragment was isolated from a *Sall*-*EcoRI* digest of pCGP147; pCGP158: a 900 bp fragment was obtained by PCR with oligos 3 and 4 using pCGP158 DNA as template; pCGP160: a 600 bp fragment was isolated from a *PstI*-*EcoRV* digest of pCGP160; pCGP454: fragment was obtained by PCR with oligos 3 and 5 using pCGP454 DNA as template. All purified fragments were labelled with <sup>32</sup>P-dCTP as described in Example 1.

Figure 2(B) to (H) show partial nucleotide sequences and the corresponding predicted amino acid translation products for the cDNA inserts from (i) pCGP142, (ii) pCGP147, (iii) pCGP158, (iv) pCGP160 and (v) pCGP454. The regions used to probe cDNA library #1 to isolate related clones have been delineated by arrowheads.



Figure 3(A) to (D) is the nucleotide sequence and predicted amino acid sequence for the cDNA insert from pCGP602. Two probes that included the sequences between the internal HincII-EcoRV and EcoRV-HindIII sites were used to identify  
5 related sequences in a group of cytochrome P450 homologues.

Figures 4(A) and 4(B) show partial nucleotide sequence for the cDNA inserts from:  
4(A): 1) pCGP161; 2) pCGP162; 3) pCGP163; 4) pCGP165; 5) pCGP166; 6) pCGP167, and 4(B): 7 pCGP168; 8) pCGP169; 9) pCGP171 and 10) pCGP173.  
10 A mixed probe that included the cDNA inserts of all these clones was used to screen cDNA library #2 for related sequences.

Figure 5 is the nucleotide sequence and predicted amino acid sequence for the cDNA insert from pCGP619.  
15

Figure 6 shows a diagrammatic representation of a restriction enzyme map of pCGP619. Partial lengths of the cDNA insert are indicated by the bolder lines with solid ends (as opposed to arrows). These were subcloned into M13-mp18 and mp19 and sequenced using oligonucleotide primer sequences, as indicated, to obtain  
20 overlapping sequence information. The extent and direction of sequence information obtained from each subcloned piece is shown by lines with arrowheads. Primer -40 was used unless otherwise specified. 190 = primer sequence 190; 191 = primer sequence 191; poly T = poly T oligonucleotide was used as primer; ds seq = sequence was read with double-stranded DNA; ATG indicates the methionine  
25 initiation codon and the total length of the clone in base pairs is also indicated.

Figure 7 shows a 3'-hydroxylase assay of yeast extracts using <sup>3</sup>H-naringenin as substrate. The autoradiograph shows conversion of <sup>3</sup>H-naringenin to the 3'-hydroxylated derivative eriodictyol by an extract of yeast transformed with the  
30 plasmid pCGP621 (1, 2). No 3'-hydroxylase activity was detected in untransformed yeast (C).

Figure 8 shows nucleotide sequence and predicted amino acid sequence for the insert from pCGP635. These sequences may be used as probes for the isolation of putative rose 3'-hydroxylase cDNA clones.

- 5 Figure 9 shows nucleotide sequence and predicted amino acid sequence for the insert from pCGP772. These sequences may be used as probes for the isolation of putative carnation 3'-hydroxylase cDNA clones.

- 10 Figure 10 shows nucleotide sequence and predicted amino acid sequence for the insert from pCGP773. These sequences may be used as probes for the isolation of carnation putative 3'-hydroxylase cDNA clones.

- 15 Figure 11 shows partial nucleotide sequence and predicted amino acid sequence for insert from pCGP854. These sequences were used as a probe to select a putative 3'-hydroxylase cDNA clone. Underlined amino acids are identical to those of the cDNA insert from pCGP619 between positions 971 and 1091.

- 20 The disarmed microorganism *Agrobacterium tumefaciens* strain AGL0 containing the plasmid pCGP809 was deposited with the Australian Government Analytical Laboratories, 1 Suakin Street, Pymble, New South Wales, 2037, Australia on March 24, 1993 and was given Accession Number

**EXAMPLE 1**  
**ISOLATION OF 3'-HYDROXYLASE AND RELATED NUCLEIC**  
**ACID SEQUENCES**

5

**1. Materials and methods**

**Chemicals Enzymes and Radioisotopes**

10 Eriodictyol was obtained from Carl Roth KG and naringenin was obtained from Sigma. [<sup>3</sup>H]-Naringenin (5.7 Ci/mmole) was obtained from Amersham. All enzymes were obtained from commercial sources and used according to the manufacturer's recommendations.

**Bacterial Strains**

15 The *Escherichia coli* strains used were:

- |    |                    |   |
|----|--------------------|---|
| 20 | DH5a               | supE44, Δ(lacZYA-ArgF)U169, ϕ80lacZΔM15, hsdR17 (r <sub>k</sub> <sup>-</sup> , m <sub>k</sub> <sup>+</sup> ), recA1, endA1, gyrA96, thi-1, relA1, deoR. (Hanahan, 1983 and BRL, 1986).  |
| 25 | XL1-Blue           | supE44, hsdR17 (r <sub>k</sub> <sup>-</sup> , m <sub>k</sub> <sup>+</sup> ), recA1, endA1, gyrA96, thi-1, relA1, lac <sup>-</sup> , [F <sup>+</sup> proAB, lacI <sup>q</sup> , lacZΔM15, Tn10(tet <sup>r</sup> )] (Bullock <i>et al</i> , 1987).                |
| 30 | PLK-F <sup>+</sup> | recA, hsdR17 (r <sub>k</sub> <sup>-</sup> , m <sub>k</sub> <sup>+</sup> ), mcrA <sup>-</sup> , mcrB <sup>-</sup> , lac <sup>-</sup> , supE44, galK2, galT22, metB1, [F <sup>+</sup> proAB, lacI <sup>q</sup> , lacZΔM15, Tn10(tet <sup>r</sup> )] (Stratagene). |
|    | SOLR               | e14 <sup>-</sup> (mcrA), Δ(mcrCB-hsdSMR-mrr)171, sbcC, recB, recJ, umuC::Tn5(kan <sup>r</sup> ), uvrC, lac, gyrA96, thi-1, relA1, [F <sup>+</sup> proAB, lacI <sup>q</sup> ZΔM15], Su <sup>-</sup> (non-suppressing) (Stratagene)                               |

The disarmed *Agrobacterium tumefaciens* strain AGL0 (Lazo et al., 1991) was obtained from R Ludwig (Department of Biology, University of California, Santa Cruz).

5

The cloning vector pBluescript was obtained from Stratagene.

#### Transformation of *E. coli* and *A. tumefaciens*

Transformation of the *E. coli* strain DH5a cells was performed according to the  
10 method of Inoue et al (1990).

The plasmid pCGP809 was introduced into the *Agrobacterium tumefaciens* strain AGL0 by adding 5 mg of plasmid DNA to 100 mL of competent AGL0 cells prepared by inoculating a 50 mL MG/L (Garfinkel and Nester, 1980) culture and  
15 growing for 16 h with shaking at 28°C. The cells were then pelleted and resuspended in 0.5 mL of 85% (v/v) 100 mM CaCl<sub>2</sub>/15% (v/v) glycerol. The DNA-*Agrobacterium* mixture was frozen by incubation in liquid N<sub>2</sub> for 2 min and then allowed to thaw by incubation at 37°C for 5 min. The DNA/bacterial mixture was then placed on ice for a further 10 min. The cells were then mixed with 1 mL of MG/L media and  
20 incubated with shaking for 16 h at 28°C. Cells of *A. tumefaciens* carrying pCGP809 were selected on MG/L agar plates containing 100 mg/mL gentamycin. The presence of pCGP809 was confirmed by Southern analysis of DNA isolated from the gentamycin-resistant transformants.

#### 25 Plant Material

Seed of the *Petunia* F<sub>1</sub> hybrid "Old Glory Blue" (OGB) was obtained from Ball Seed, USA.

*Chrysanthemum morifolium* cultivars were obtained from Baguley Flower and Plant  
30 Growers, Victoria.

Flowers of *Dianthus caryophyllus* cv. Laguna and *Rosa hybrida* cv. Kardinal were obtained from Van Wyk and Son Flower Supply, Victoria.

- 5 Plants were grown in specialised growth rooms with a 14 hr day length at a light intensity of 10,000 lux minimum and a temperature of 22 to 26°C.

Five stages of *Petunia* flower development were defined as follows:

- 10 Stage 1: Unpigmented, closed bud (<25 mm in length).  
Stage 2: Pigmented, closed bud (25-35 mm in length).  
Stage 3: Dark purple bud with emerging corolla (>35 mm in length).  
Stage 4: Dark purple opened flower pre-anther dehiscence (>50 mm in length).  
Stage 5: Fully opened flower with all anthers dehisced.

15

Stages of *Chrysanthemum* flower development were defined as follows:

- Stage 0: No visible flower bud.  
Stage 1: Flower bud visible: florets completely covered by the bracts.  
20 Stage 2: Flower buds opening: tips of florets visible.  
Stage 3: Florets tightly overlapped.  
Stage 4: Tips of nearly all florets exposed; outer florets opening but none horizontal.  
Stage 5: Outer florets horizontal.  
25 Stage 6: Flower approaching maturity.

Stages of *Dianthus caryophyllus* flower development were defined as follows:

- Stage 1: No visible flower bud.  
30 Stage 2: Flower buds opening: tips of florets visible.  
Stage 3: Tips of nearly all florets exposed; outer florets opening, none horizontal.

Stage 4: Outer florets horizontal.

Stages of *Rosa hybrida* flower development were defined as follows:

- 5 Stage 1: Unpigmented, tightly closed bud (10-12mm high; 5mm wide).  
Stage 2: Pigmented, tightly closed bud (15mm high ; 9mm wide).  
Stage 3: Pigmented, closed bud; sepals just beginning to open (20-25mm high;  
13-15mm wide)  
10 Stage 4: Flower bud beginning to open; petals heavily pigmented; sepals have  
separated (bud is 25-30mm high and 18mm wide).  
Stage 5: Sepals completely unfolded; some curling. Petals are heavily  
pigmented and unfolding (bud is 30-33mm high and 20mm wide).

#### Construction of cDNA library #1

- 15 Twenty grams of stage 3 to 4 *Petunia* cv. OGB flower limbs tissue was homogenised  
in 100 mL of PEB (200 mM Tris-HCl (pH 8.6), 60 mM KCl, 30 mM MgCl<sub>2</sub>, 25 mM  
EGTA) containing 10 mM vanadyl ribonucleoside complex. Cell debris was removed  
by filtering the homogenate through sterile Miracloth (Calbiochem). The filtrate was  
layered on top of a step gradient of 6 mL of PEB containing 25% (w/v) sucrose, 250  
20 units InhibitAce (5-Prime 3-Prime), and 6 mL of PEB containing 50% (w/v) sucrose  
and 250 units InhibitAce in Ultra-Clear™ Quick-Seal™ (Beckman) centrifuge tubes.  
The tubes were centrifuged for 3.5 h at 26,000 rpm in a 70Ti rotor. Membrane-  
bound polysomes were collected from the 25% sucrose/50% sucrose interface and  
added to a 4 M guanidium isothiocyanate solution. RNA was isolated from the  
25 denatured polysomes by pelleting through a 5.7 M CsCl cushion, as described by  
Turpen and Griffith (1986).

A Uni-ZAP™ XR vector kit (Stratagene) was used to construct a directional cDNA  
library in ZAP using 25 µg of the polysomal RNA as template. The primary library,  
30 which contained 250,000 plaque forming units (pfu), was amplified by overnight  
growth on NZY plates (Sambrook *et al.*, 1989) and the amplified phage stock was  
eluted in PSB (100 mM NaCl, 8 mM MgSO<sub>4</sub>, 50 mM Tris-HCl (pH 7.5), 0.01%

- 20 -

(w/v) gelatin) as described by Sambrook *et al.*, (1989).

#### Construction of cDNA library #2

Total RNA was isolated from the petal tissue of *P. hybrida* cv. OGB stage 3 to 4 flowers using the method of Turpen and Griffith (1986). Poly(A)<sup>+</sup> RNA was selected from the total RNA by three cycles of oligo-dT cellulose chromatography (Aviv and Leder, 1972).

Two micrograms of poly(A)<sup>+</sup> RNA were reverse transcribed in a 20 µL volume containing 1 x Superscript<sup>TM</sup> reaction buffer, 10 mM dithiothreitol (DTT), 500 µM dATP, 500 µM dGTP, 500 µM dTTP, 500 µM 5-methyl-dCTP, 0.75 µg oligonucleotide #6 and 2 µL Superscript<sup>TM</sup> reverse transcriptase (BRL). The reaction mix was incubated at 37°C for 50 min, 44°C for 10 min, then placed on ice.

Second strand reaction mix (140 µL) was added to the first strand reaction. The second strand reaction mix consisted of 21 mM Tris-HCl, 104 mM KCl, 5.3 mM MgCl<sub>2</sub>, 171 µM b-NAD, 11.4 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 214 µM dATP, 642 µM dCTP, 214 µM dGTP, 214 µM dTTP, 4 mM DTT, 10 µCi <sup>32</sup>P-dCTP (3000 Ci/mMole), 15 units *E.coli* DNA ligase, 40 units DNA polymerase (Boehringer) and 0.8 units RNase H. The final mixture was incubated for 150 min at 16°C. To make the double-stranded cDNA blunt-ended, 10 units T4 DNA polymerase was added, and the reaction continued for a further 15 min at 16°C. The reaction was stopped and the cDNA purified by phenol/chloroform extraction, followed by chloroform extraction and ethanol precipitation.

EcoRI adaptors (Promega) were ligated with the cDNA and then kinased using conditions recommended by the manufacturer. The enzymes were denatured by heat (70°C, 20 min) and the DNA was purified by phenol/chloroform extraction and ethanol precipitation. The cDNA was digested with 50 units XhoI (Boehringer) in a reaction volume of 100 µL, using conditions recommended by the manufacturer. The enzyme was heat killed (70°C, 20 min) and the mixture passed through an S400 spun column (Pharmacia) which had been equilibrated in STE buffer (Sambrook *et*

SUBSTITUTE SHEET
------------------



*al.*, 1989).

The eluate was phenol/chloroform extracted and ethanol precipitated. After microcentrifugation at 4°C for 30 min the cDNA pellet was rinsed with 70% (v/v) ethanol, air dried and resuspended in 10 µL of TE buffer (10 mM Tris-HCl (pH7.5), 1 mM EDTA).

NA-45 membrane (Schleicher and Schuell) was used to isolate cDNA in the size range of 1.3 to 2.5kb from a 7.5 µL sample that had been electrophoresed through a 1% (w/v) agarose gel.

The size fractionated cDNA was ligated with 1 µg ZAPII EcoRI/XhoI/ CIAP treated vector (Stratagene) in 5 µL reaction buffer consisting of 50 mM Tris-HCl (pH 7.0), 10 mM MgCl<sub>2</sub>, 10 mM DTT, 1 mM ATP and 2 units T4 DNA ligase. The reaction was performed at 4°C for 2 days.

After leaving at room temperature for 2 h, the ligation reaction mixture was packaged using the Packagene system (Promega). The total number of recombinants was 270,000 pfu.

An amount of 150,000 pfu of the packaged cDNA was plated at 10,000 pfu per 15 cm diameter plate after transfecting PLK-F' cells. The plates were incubated at 37°C for 8 h, then stored overnight at 4°C. Duplicate lifts were taken onto Colony/Plaque Screen™ filters (DuPont) and treated as recommended by the manufacturer.

**Construction of cDNA library #3**

Total RNA was isolated from the petal tissue of *Chrysanthemum morifolium* cv. Dark Pink Pompom (Reference Number 5999), stages 1, 2 and 3 flowers, again using the method of Turpen and Griffith (1986). Poly(A)<sup>+</sup> RNA was selected from the total RNA, as for *P. hybrida*, by three cycles of oligo-dT cellulose chromatography (Aviv and Leder, 1972). Two micrograms of poly(A)<sup>+</sup> RNA were used as template for cDNA synthesis, as outlined above for *P. hybrida*.

- 22 -

Following fractionation and ligation, the cDNA reaction mixture was packaged using the Packagene system (Promega). The total number of recombinants was 37,000 pfu.

5 An amount of 300,000 pfu (of amplified library) of the packaged cDNA was plated at 20,000 pfu per 15 cm diameter plate after transfecting XL1-Blue cells. The plates were incubated at 37°C for 8 h, then stored overnight at 4°C. Duplicate lifts were taken onto Colony/Plaque Screen™ filters (DuPont) and treated as recommended by the manufacturer.

10

### Preparation of PCR templates

#### 1. Plasmid DNA

DNA was isolated using an alkaline lysis procedure (Sambrook *et al.*; 1989). Plasmid DNA was further purified by banding on a CsCl gradient. This DNA was used as  
15 template for PCR.

#### 2. *Chrysanthemum* genomic DNA

For isolation of total DNA, 5 g of *Chrysanthemum* petal tissue was frozen in liquid nitrogen and ground to a fine powder in a cold mortar and pestle. Ground tissue  
20 was extracted in 5 mL of phenol:chloroform, followed by 5 mL of NTMES buffer (0.01 M NaCl; 0.1 M Tris pH 8.5; 5 mM MgCl<sub>2</sub>; 1 mM EDTA; 1% SDS). The aqueous phase was re-extracted with 5 mL of phenol:chloroform and the aqueous phase collected after centrifugation. DNA was spooled from this solution after addition of 0.5 mL 3M NaAc, pH 5.8 and two volumes of ethanol. The final pellet  
25 was resuspended in 2 mL TE buffer and the concentration determined prior to use in PCR.

#### 3. *Dianthus* cDNA

Total RNA was isolated from the petal tissue of *D. caryophyllus* cv. Laguna stage 3  
30 flowers, likewise using the method of Turpen and Griffith (1986). Poly(A)<sup>+</sup> RNA was selected from the total RNA by Oligotex dT-30 (Takana, Japan) following the manufacturer's protocol, and two micrograms were reverse transcribed using

SUBSTITUTE SHEET
------------------

Superscript™ reverse transcriptase as recommended by the manufacturer. The cDNA was dissolved in 10 mL TE buffer. For PCR reactions, 5 mL were used as template. Conditions for PCR are described below.

5 4. *Rosa* cDNA

Total RNA was prepared from the buds of *Rosa hybrida* cv. Kardinal stage 1. At this stage, buds were 1.0 - 1.2 cm high and approximately 0.5 cm wide. They were completely closed and no pigment was visible when the sepals were dissected away.

- 10 Frozen tissue (1-3 g) was ground in liquid nitrogen with a mortar and pestle, placed in 25 mL pre-chilled Buffer A [0.2 M boric acid, 10 mM EDTA (sodium salt) (pH 7.6)] and homogenized briefly. The extract was mixed on a rotary shaker until it reached room temperature and an equal volume of phenol/chloroform (1:1 v/v), equilibrated with Buffer A, was added. After mixing for a further 10 min, the RNA  
15 preparation was centrifuged at 10,000 x g for 10 min at 20° C. The upper aqueous phase was retained and the phenol interface re-extracted as above. The aqueous phases were pooled and adjusted to 0.1 M sodium acetate (pH 6.0), 2.5 volumes 95% ethanol were added and the mixture was stored at -20° C overnight.
- The preparation was centrifuged at 10,000 x g for 10 min at 4° C, the pellet dissolved  
20 gently in 20 mL Buffer B [25 mM boric acid, 1.25 mM EDTA (sodium salt), 0.1 M NaCl (pH 7.6)] and 0.4 volumes 2-butoxyethanol (2BE) were added. This solution was incubated on ice for 30 min. It was then centrifuged at 10,000 x g for 10 min at 0° C and the supernatant carefully collected. After addition of 1.0 volume of 2BE and incubation on ice for a further 30 min, the supernatant was again centrifuged at  
25 10,000 x g for 10 min at 0° C. The resulting pellet was gently washed with Buffer A : 2BE (1 : 1 v/v), then with 70% (v/v) ethanol, 0.1 M potassium acetate and finally with 95% ethanol. The pellet was air dried and dissolved in 1 mL diethyl pyrocarbonate (DEPC)-treated water. This was adjusted to 3 M lithium chloride, left on ice for 60 min and centrifuged at 10,000 x g for 10 min at 0° C. The pellet was  
30 washed twice with 3 M LiCl and then with 70% ethanol, 0.1 M potassium acetate.

- 24 -

The resulting RNA pellet was dissolved in 400 mL DEPC-treated water and extracted with an equal volume phenol/chloroform. The RNA mix was then centrifuged at 10,000 x g for 5 min at 20° C, the aqueous phase collected and made  
 5 to 0.1 M sodium acetate, and a further 2.5 volumes of 95% ethanol were added. After 30 min incubation on ice, the mix was centrifuged at 13,000 rpm (5,000 x g) for 20 min at 20° C and the RNA pellet resuspended gently in 400 mL DEPC-treated water.

- 10 Poly(A)<sup>+</sup> RNA was selected from the total RNA by Oligotex dT-30 (Takana, Japan) following the manufacturer's protocol.

Double-stranded cDNA was synthesized from 2 mg poly(A)<sup>+</sup> RNA using the same method as described above for the construction of the *Petunia* cDNA library # 2.

- 15 The cDNA was dissolved in 10 mL TE buffer.

#### Synthesis of Oligonucleotides

Oligonucleotides and primers were synthesized on an Applied Biosystems PCR-Mate DNA synthesizer using methods recommended by the manufacturer. The  
 20 oligonucleotides and primers synthesized were, 5'-3':

- Oligo 1: GTTCAATTCGGAATGATG  
 Oligo 2: GCTGCACTTAATCCATAT  
 Oligo 3: GGATGACTCAAACAGCTATGACCATG  
 25 Oligo 4: TGCATAGCTTTTGGG  
 Oligo 5: CCIGG(A/G)CAIATIC(G/T)(C/T)(C/T)TICCIGCICC(A/G)AAIGG  
 Oligo 6:  
 GAGAGAGAGAGAGAGAGATCTCGAGTTTTTTTTTTTTTTTTTT  
 Oligo 7: CCIGC(A/G)CAIATIC(G/T)IC(T/G)ICCIGCICC(A/G)AAIGG  
 30 primer -40 GTTTTCCCAGTCACGAC  
 primer 190 TTGGAGTGGGCAATGGC  
 primer 191 CTGCTGCAAACAAGTCC

SUBSTITUTE SHEET
------------------

poly-T        TTTTTTTTTTTTTTTT(AGC)

The basis for the design of oligo 5 was as follows: Amino acid sequences from the putative haem-binding domain of an avocado cytochrome P450 (Bozak *et al*, 1990) and the corresponding sequences encoded by the two petunia cytochrome P450 homologues pCGP142 and pCGP147 were aligned:

	avocado	P	F	G	A	G	R	R	G	C	P	G
	pCGP142	P	F	G	A	G	K	R	I	C	P	G
10	pCGP147	P	F	G	S	G	R	R	I	C	P	G

The consensus amino acid sequence of the haem-binding region for the three plant cytochromes P450 could thereby be seen to be:

15                    P F G A(S) G R(K) R I(G) C P G

Possible permutations of nucleotide sequence that could encode the amino acids found in the haem-binding domain of the three cytochrome P450 molecules could then be deduced:

20                    5' - CCX TTT GGX GCX GGX AGX CGX ATX TGT CCX GGX -3'  
                                  C        AG            CA    A    GG        C  
  T

25    X indicates nucleotide positions where all four nucleotides (A,C,G and T) can be used. Oligo 5 was designed to complement a subset of the consensus sequence derived from the three plant cytochromes P450. Deoxyinosine (I) was used predominantly when base degeneracy was greater than three. The resulting oligonucleotide sequence was as shown above.

30

### Polymerase Chain Reactions

#### 1. Amplification of cloned cytochrome P450 sequences

For amplification of cloned *Petunia* cytochrome P450 sequences, PCR mixes  
5 contained 100 ng of plasmid template, 10 mM Tris- HCl (pH 8.3), 50 mM KCl,  
1.25 mM MgCl<sub>2</sub>, 0.2 mM each dNTP, 1.0 µM each primer and 0.5 unit AmpliTaq  
DNA Polymerase (Cetus). Reaction mixes (100 µl) were cycled 30 times between  
95°C for 1 min, 42°C for 1 min and 72°C for 2 min.

#### 10 2. Amplification of *Dianthus* sequences related to *Petunia* 3'- hydroxylase

PCR mixes contained 100 ng of cDNA template, 10 mM Tris- HCl (pH 8.3), 50  
mM KCl, 1.5 mM MgCl<sub>2</sub>, 0.001% (w/v) gelatin, 0.2 mM each dNTP, 1.0 µM each  
primer and 5 units AmpliTaq DNA Polymerase (Cetus). Reaction mixes (100 µl)  
15 were cycled firstly through 95°C for 3 min, 55°C for 1 min and 72°C for 1 min,  
then through a further 39 cycles between 95°C, 55°C and 72°C each for 1 min.  
Amplified products were gel-purified using Seaplaque low melting agarose (FMC).  
The mixture was heated until the agarose melted and extracted with TE-saturated  
phenol. The aqueous phase was then extracted with phenol/chloroform and the  
amplified products precipitated with ethanol. Following gel-purification, the  
20 amplified products were cloned directly into the ddT-tailed pBluescript vector  
described by Holton and Graham (1991).

#### 3. Amplification of *Chrysanthemum* sequences related to *Petunia* 3'- hydroxylase

25 *Chrysanthemum* reaction mixes contained 200 ng of genomic DNA template, 10  
mM Tris- HCl (pH 8.3), 50 mM KCl, 2.5 mM MgCl<sub>2</sub>, 0.001% (w/v) gelatin, 0.2  
mM each dNTP, 1.0 µM each primer and 5 units AmpliTaq DNA Polymerase  
(Cetus). Reaction volumes of 50 µL were cycled 35 times between 95°C, 55°C  
and 72°C, each for 90 s. Amplified products were gel-purified using GeneClean  
30 (Bio 101 Inc.) and cloned directly into the ddT-tailed pBluescript vector described  
by Holton and Graham (1991).

#### 4. Amplification of *Rosa* sequences related to *Petunia* 3'-hydroxylase

*Rosa* reaction mixes contained 1  $\mu$ L of a 10-fold dilution of ds cDNA prepared as described above, 10 mM Tris- HCl (pH 8.3), 50 mM KCl, 2.5 mM  $MgCl_2$ , 0.001% (w/v) gelatin, 0.2 mM each dNTP, 1.0  $\mu$ M each primer and 5 units AmpliTaq

- 5 DNA Polymerase (Cetus). Reaction volumes of 50  $\mu$ L were cycled 30 times between 95°C for 1 min, 55°C for 1 min and 72°C for 3 min. Amplified products were gel-purified using Geneclean (Bio 101 Inc.) and cloned directly into the ddT-tailed pBluescript vector described by Holton and Graham (1991).

#### 10 Screening of cDNA Libraries

Duplicate plaque lifts from cDNA library #2 were hybridized and washed as follows: High stringency conditions (hybridization: 50% (v/v) formamide, 6 x SSC, 1% (w/v) SDS at 42°C for 16 h and washing: 2 x SSC, 1% SDS at 65°C for 2 x 15 min followed by 0.2 x SSC, 1% SDS at 65°C for 2 x 15 min) were used to detect

- 15 sibling clones and low stringency conditions (hybridization: 20% formamide, 6 x SSC, 1% SDS at 42°C for 16 h and washing: 6 x SSC, 1% SDS at 65°C for 1 h) were used to detect related sequences.

- Lifts from cDNA library #3 were hybridized and washed as follows: For the  
20 primary screening, using the *Petunia* 3'-hydroxylase cDNA EcoRI-XhoI insert from pCGP619 (see Figure 6), hybridization conditions were 20% (v/v) formamide, 1 M NaCl, 10% (w/v) dextranulphate at 37°C for 16 h and washing conditions were 0.1 x SSC, 1% (w/v) SDS at room temperature. For the secondary screening, using the EcoRI-XhoI insert from pCGP854, conditions were identical except that  
25 the hybridization reaction took place at 42°C for 16 h.

#### <sup>32</sup>P-Labeling of DNA Probes

- DNA fragments (50 to 100 ng) were radioactively labelled with 50  $\mu$ Ci of [ $\alpha$ -<sup>32</sup>P]-dCTP using an oligolabelling kit (Bresatec). Unincorporated [ $\alpha$ -<sup>32</sup>P]-dCTP was  
30 removed by chromatography on a Sephadex G-50 (Fine) column.



### DNA Sequence Analysis

DNA sequencing was performed essentially by the method of Sanger *et al.* (1977) using the Sequenase enzyme (USB, version 2.1). The complete sequence of clones  
5 pCGP602 and pCGP619 was determined by compilation of sequence from different M13 -mp18 and -mp19 (Norrandar *et al.*, 1983; Yanisch-Perron, 1985) subclones obtained using standard cloning procedures (Sambrook *et al.*, 1989). For some regions it was necessary to synthesise specific oligonucleotide primers to obtain overlapping sequence data, including primers -40, 190 191 and poly-T.

10

A restriction map of pCGP619 showing the position of several of these sequences may be seen in Figure 6.

Homology searches against Genbank, SWISS-PROT and EMBL databases were  
15 performed using the FASTA and TFASTA programs (Pearson and Lipman, 1988).

### 3'-Hydroxylase Assay

3'-Hydroxylase enzyme activity was measured using a modified version of the  
20 method described by Stotz and Forkmann (1982). The assay reaction mixture typically contained 100  $\mu$ L of yeast extract, 5  $\mu$ L of 50 mM NADPH in assay buffer (100 mM potassium phosphate (pH8.0), 1 mM EDTA and 20 mM 2-mercaptoethanol) and 10  $\mu$ Ci of [ $^3$ H]- naringenin and was made up to a final volume of 210  $\mu$ L with the assay buffer. Following incubation at 23°C for 2-16 h,  
25 the reaction mixture was extracted with 0.5 mL of ethylacetate. The ethylacetate phase was dried under vacuum and then resuspended in 10  $\mu$ L of ethylacetate. The tritiated flavonoid molecules were separated on cellulose thin layer plates (Merck Art 5577, Germany) using a chloroform: acetic acid: water (10:9:1 v/v) solvent system. At the completion of the chromatography the TLC plates were  
30 sprayed with 7% 2,5-diphenyloxazol in diethyl ether. The reaction products were localised by autoradiography and identified by comparison to non-radioactive naringenin and eriodictyol standards which were run alongside the reaction

- 29 -

products and visualised under UV light.

#### Construction of pCGP621

A 1.8 kb EcoRI-XhoI fragment that included the entire cDNA insert from pCGP619 was ligated with the 8 kb EcoRI-SalI fragment from pYHCC101 (Tanaka *et al.*, 1988). The resulting plasmid, pCGP621, contained the pCGP619 cDNA fragment ligated in a sense orientation behind the yeast glyceraldehyde-3-phosphate dehydrogenase promoter.

#### 10 Yeast transformation

The yeast strain G-1315 (Mat a, trp1) (Ashikari *et al.*, 1989) was transformed with pCGP621 according to Ito *et al.* (1983). The transformants were selected by their ability to restore G-1315 to tryptophan prototrophy.

#### 15 Preparation of yeast extracts for assay of 3'-hydroxylase activity

A single isolate of G-1315/pCGP621 was used to inoculate 20 ml of YNBC [1.2% (w/v) yeast nitrogen base without amino acids (Difco), 2% (w/v) glucose and 0.3% (w/v) casamino acid (Difco)] which was subsequently incubated for 2 days at 30°C. Cells were collected by centrifugation, washed once with TE buffer, once with buffer A [10 mM Tris-HCl (pH 7.5), 0.65 M sorbitol, 0.1 mM DTT, 0.1 mM EDTA], and then resuspended in buffer B [10 mM Tris-HCl, (pH7.5), 1.2 M sorbitol, 0.1 mM DTT, 0.1 mM EDTA] containing zymolyase (0.1 mg/mL) (Seikagaku-kogyo, Japan). Following incubation for 1 h at 30°C the cells were pelleted by centrifugation and resuspended in 400 µL of buffer A. The cell suspension was then vortexed with glass beads (diameter = 0.4 mm) for 2 min and a 100 µL sample was assayed for activity.

#### Construction of pCGP293

The expression binary vector pCGP293 was derived from the Ti binary vector pCGN1559 (McBride and Summerfelt, 1990). Plasmid pCGN1559 was digested with KpnI and the overhanging 3' ends were removed with T4 DNA polymerase according to standard protocols (Sambrook *et al.*, 1989). The vector was then

SUBSTITUTE SHEET
------------------

- 30 -

further digested with *Xba*I and the resulting 5' overhang was repaired using the Klenow fragment of DNA polymerase I. The vector was then re-ligated to give pCGP67. A 1.97 kb *Pst*I fragment containing the Mac promoter, mas terminator and various cloning sites (Comai *et al.*, 1990) was isolated from pCGP40 and  
5 inserted into the *Pst*I site of pCGP67 to give pCGP293.

Plasmid pCGP40 was constructed by removing the GUS gene (Jefferson *et al.*, 1987) as a *Bam*HI-*Sac*I fragment from pCGN7334 and replacing it with the *Bam*HI-*Sac*I fragment from pBluescribe M13 that includes the multicloning site.  
10 Plasmid pCGN7334 (obtained from Calgene Inc., CA, USA), was constructed by inserting the fragment containing the Mac-GUS-mas gene fusion into the *Xho*I site of pCGN7329 (Comai *et al.*, 1990).

#### Construction of pCGP809

15 Plasmid pCGP809 was constructed by cloning the cDNA insert from pCGP619 in a sense orientation behind the Mac promoter (Comai *et al.*, 1990) of pCGP293. The 1.8 kb *Bam*HI-*Kpn*I fragment containing the cDNA insert was isolated from pCGP619 and ligated with a *Bam*HI-*Kpn*I digest of pCGP293. Correct insertion of the insert in pCGP809 was established by restriction analysis of DNA isolated  
20 from gentamycin-resistant transformants.

#### *Petunia* Transformation

##### a. Plant material

*Petunia hybrida* (Skr4 x Sw63) seeds were sterilized in 1.25% (w/v) sodium  
25 hypochlorite for 10 minutes and rinsed three times in sterile water. Sterilized seeds were soaked in 100 mg/L gibberellic acid (GA<sub>3</sub>) solution for 16 to 20 h. They were then germinated for 2 weeks on 10% (w/v) MS (Murashige and Skoog, 1962) medium supplemented with 1% (v/v) sucrose and 0.8% (w/v) Difco Bacto agar. Young seedlings were transferred to MS medium supplemented with 3% (w/v)  
30 sucrose for 3 weeks before being transferred to Jiffy peat pellets (Jiffy Products Ltd, Norway), kept under mist and illuminated (135  $\mu$ E. mercury halide light, 22°C) for 2 to 3 weeks. These young plants were then transferred to a growth

SUBSTITUTE SHEET
------------------

cabinet (68  $\mu$ E. cool white fluorescent light, 25°C). For co-cultivation, young leaves were harvested and sterilized in 1.3% (w/v) sodium hypochlorite for 2 min followed by rinsing three times in sterile water. Leaf tissue was then cut into 25 mm<sup>2</sup> squares and precultured on MS media supplemented with 0.05 mg/L kinetin  
5 and 1.0 mg/L 2,4-dichlorophenoxyacetic acid (2,4-D) for 24 h.

b. Co-cultivation of *Agrobacterium* and *Petunia* tissue

*Agrobacterium tumefaciens* strain AGL0 (Lazo *et al.*, 1991) containing the binary vector pCGP809 was maintained at 4°C on MG/L (Garfinkel and Nester, 1980)  
10 agar plates with 100 mg/L gentamycin. A single colony was grown overnight in liquid medium containing 1% (w/v) Bacto-peptone, 0.5% (w/v) Bacto-yeast extract and 1% (w/v) NaCl. A final concentration of  $5 \times 10^8$  cells/mL was prepared the next day by dilution in liquid MS medium containing 3% (w/v) sucrose (BPM). Leaf discs were dipped for 5 min into BPM containing AGL0/pCGP809. The leaf  
15 discs were then blotted dry and placed on co-cultivation media for 4 days. The co-cultivation medium consisted of SH medium (Schenk and Hilderbrandt, 1972) supplemented with 0.05 mg/L kinetin and 1.0 mg/L 2,4-D and included a feeder layer of tobacco cell suspension spread over the co-cultivation medium with a filter paper placed on top of the tobacco cell suspension.

20

c. Recovery of transgenic petunia plants

After co-cultivation, the leaf discs were transferred to selection media consisting of fresh MS medium supplemented with 3% (w/v) sucrose, 2 mg/L  $\alpha$ -benzylaminopurine (BAP), 100 mg/L kanamycin, 350 mg/L cefotaxime, 0.3%  
25 (w/v) Gelrite Gellan Gum (Schweizerhall). After 3 weeks, regenerating explants were transferred to fresh medium. Adventitious shoots which survived the kanamycin selection were isolated and transferred to BPM containing 100 mg/L kanamycin and 350 mg/L cefotaxime for root induction. All cultures were maintained under a 16 h photoperiod (60  $\mu$ E. cool white fluorescent light) at 23  
30  $\pm$  2°C. When roots reached 2-3 cm in length the transgenic petunia plantlets were transferred to autoclaved Debco 51410/2 potting mix in 8 cm tubes. After 4 weeks plants were replanted into 15 cm pots using the same potting mix and maintained

- 32 -

at 23°C under a 14 h photoperiod (300 µE. mercury halide light).

## 2. Results

### 5 Isolation of cytochrome P450 homologues from cDNA library #1

The isolation of five petunia cDNA clones that have regions of sequence similarity with cytochrome P450 enzymes has been described previously (International Patent Application No. PCT/AU92/00334). Partial sequences of these clones, designated pCGP142, pCGP147, pCGP158, pCGP160 and pCGP454, are shown in Figure 2.

- 10 A mixed probe of <sup>32</sup>P-labelled DNA fragments that included the coding regions of these five cytochrome P450 homologues (see Figures 2A and B) was used to screen 50,000 recombinants from cDNA library #1 for related sequences. A total of 152 hybridizing clones were detected under low stringency hybridization and washing conditions. A further 13 different cytochrome P450 homologues were identified  
15 by sequence analysis of DNA isolated from the hybridizing clones.

One of these clones, designated pCGP174, was shown to correspond to the Hf1 locus of Petunia (see International Patent Application No. PCT/AU92/00334).

- The nucleotide sequence of a full-length version of this clone, pCGP602, isolated  
20 from cDNA library #2 is shown in Figure 3. Ten of the thirteen other cytochrome P450 homologues isolated in the screen, pCGP161, pCGP162, pCGP163, pCGP165, pCGP166, pCGP167, pCGP168, pCGP169, pCGP171 and pCGP173 were used as a mixed probe to screen cDNA library #2 for further cytochrome P450 homologues (see next section).

25

### Isolation of the cytochrome P450 homologue pCGP619 from *Petunia*

- A mixed probe of <sup>32</sup>P-labelled cDNA inserts from pCGP161, pCGP162, pCGP163, pCGP165, pCGP166, pCGP167, pCGP168, pCGP169, pCGP171 and pCGP173 (Figure 4) was used to screen 1.5 x 10<sup>5</sup> recombinants from cDNA library #2. Over  
30 200 hybridizing clones were detected with low stringency hybridization and washing in 2 x SSC and 1% SDS, at 65°C. Twenty-five of these clones hybridized to probes that included the internal HincII-EcoRV and EcoRV-HindIII fragments of

SUBSTITUTE SHEET
------------------

- 33 -

pCGP602 (Figure 3) under low stringency conditions, but not under high stringency conditions. Sequence analysis of this group of clones revealed that seventeen were siblings of pCGP602 (shown previously to correspond to the Hf1 locus of petunia - International Patent Application No. PCT/AU92/00334) and six were siblings of  
5 another petunia cDNA clone encoded by the Hf2 locus (International Patent Application No. PCT/AU92/00334). One clone showed no sequence homology to cytochromes P450, and one, designated pCGP619, showed 57% and 39% sequence homology to pCGP602 at the nucleotide and amino acid levels, respectively. The complete nucleotide sequence and deduced amino acid sequence  
10 of the pCGP619 cDNA are shown in Figure 5, and the restriction map outlining the sequencing strategy is shown in Figure 6.

#### Expression of pCGP619 cDNA in yeast

The cDNA insert from pCGP619 was ligated in a sense orientation behind the  
15 glyceraldehyde-3-phosphate dehydrogenase promoter in the yeast vector pYHCC101. The resulting construct, designated pCGP621, was then transformed into the yeast strain G-1315 (Ashikari *et al.*, 1989). 3'-Hydroxylase activity was detected in extracts of G-1315/pCGP621, but not in extracts of the non-transgenic yeast (Figure 7). From this it was concluded that the cDNA insert from pCGP619  
20 encoded a 3'-hydroxylase.

#### Expression of a 3'-hydroxylase cDNA in *Petunia*

The binary plasmid construct designated pCGP809 was introduced into the F<sub>1</sub> petunia hybrid Skr4 x Sw63 using *Agrobacterium*-mediated gene transfer. Leaf  
25 discs of Skr4 x Sw63 were co-cultivated with AGL0/pCGP809 and integration of the pCGP619 cDNA insert in the Skr4 x Sw63 genome was confirmed by Southern analysis of plants obtained after kanamycin selection.

The expression of the introduced 3'-hydroxylase cDNA in the Skr4 x Sw63 hybrid  
30 had a noticeable effect on flower colour. In parts of the petals of Skr4 x Sw63 the colour changed from light pink to red. The colour change observed may be described in terms of the numbers from the Royal Horticultural Society's Colour

SUBSTITUTE SHEET
------------------

- 34 -

Chart as having shifted from 55D-56C/D to 54A-55A. Other biochemical and physiological conditions will affect the individual outcome and the citing of the specific colour change achieved by expression of the 3'-hydroxylase cDNA in transgenic plants should not be interpreted as limiting the possible range of colour changes which may be observed.

#### Generation of mutants and derivatives of flavonoid 3'-hydroxylase

Using standard mutagenic techniques as hereinbefore disclosed, a range of mutants, derivatives and parts of flavonoid 3'-hydroxylase are obtainable, which may be useful in accordance with the present invention. For specific descriptions and protocols for such mutagenic techniques reference can conveniently be made to Sambrook *et al* (1989). Examples of mutants, derivatives and parts of 3'-hydroxylase which are isolatable and contemplated herein include the following:

```

15  5'   GCT AAA GAG TTT AAG GAA   3'
      Ala Lys Glu Phe Lys Glu

      5'   AAG AAA CTT CCA CCA GGT CCA TTT   3'
      Lys Lys Leu Pro Pro Gly Pro Phe

20  5'   TTG GAG TGG GCA ATG GC   3'
      Leu Glu Trp Ala Met Ala

      5'   G GAC TTG TTT GCA GCA GG   3'
25      Asp Leu Phe Ala Ala Gly

      5'   CCA TTT GGT GCT GGT CGA AGA ATT TGC CCT GG   3'
      Pro Phe Gly Ala Gly Arg Arg Ile Cys Pro Gly

```

#### 30 Detection of related sequences in plant species other than *Petunia*

Using standard Southern analysis techniques, a "nursery blot" was prepared of DNA isolated from a variety of plant species, including apple, carnation, cornflower, morning glory and rose to screen for genetic sequences related to the *petunia* 3'-hydroxylase. Results clearly showed the presence of related genetic

SUBSTITUTE SHEET
------------------



- 35 -

sequences in all the plants tested. The nursery blot comprised lanes 1 - 5 containing approximately 10 mg DNA from each of the above-mentioned species, respectively. The probe DNA used was the HindIII-EcoRV fragment from pCGP619. Southern analysis was conducted over a range of stringency conditions.

- 5 Suitable stringency conditions indicating the presence of a number of similar sequences in each species were overnight incubation in 50% formamide, 1M NaCl, 1% SDS, 10% dextran sulphate at 42°C, followed by 3 x 30 min washes in 2 x SSC, 1% SDS at 60°C.

10 **Isolation of a cytochrome P450-homologous PCR product from *Rosa***

Double-stranded rose petal cDNA, synthesized as described in Materials and Methods, was used as the template for amplification of sequences related to the petunia 3'-hydroxylase using oligonucleotides 7 and 190. A PCR product of approximately 400 bp was ligated into pBluescript and one of the recombinant  
15 plasmids recovered was designated pCGP635. The nucleotide sequence and deduced amino acid sequence of the pCGP635 insert are shown in Figure 8. This insert shows 60% similarity at the nucleotide level to the *Petunia* pCGP619 cDNA.

**Isolation of cytochrome P450-homologous PCR products from *Dianthus***

- 20 Single-stranded carnation petal cDNA synthesized as described in Materials and Methods, was used as the template for amplification of sequences related to the petunia 3'-hydroxylase using oligonucleotides 7 and 190. A PCR product of approximately 400 bp was ligated into pBluescript. Sequence analysis of the recombinant plasmids revealed that two different cytochrome P450 homologues  
25 had been amplified and cloned. Representative clones of these two molecules were designated pCGP772 and pCGP773. The nucleotide sequence and deduced amino acid sequence of each insert are shown in Figures 9 and 10, respectively. Comparison of the deduced amino acid sequences with that of other cytochrome P450s yielded the following results:

30

	pCGP772	pCGP773
pCGP619	59.2%	64.8%

SUBSTITUTE SHEET
------------------

- 36 -

pCGP158 (Haem binding area)	62.9%	61.1%
pCGP168 (Haem binding area)	59.5%	
Avocado cytochrome P450		57.8%

- 5 Isolation of a cytochrome P450-homologous PCR product from *Chrysanthemum*  
*Chrysanthemum* genomic DNA isolated as described in the Materials and Methods  
 was used as the template for amplification of sequences related to the petunia 3'-  
 hydroxylase using oligonucleotides 7 and 190. A PCR product of approximately  
 400 bp was ligated into the ddT-tailed pBluescript and one of the recombinant  
 10 plasmids recovered was designated pCGP854. The nucleotide sequence and  
 deduced amino acid sequence of 120 of these base pairs are shown in Figure 11.  
 This sequence was compared with that from the *Petunia* cDNA clone pCGP619,  
 shown in Figure 5, and shows 73% and 65% similarity at the DNA and amino acid  
 level, respectively, to the segment of sequence between positions 971 and 1091.

15

#### Isolation of a *Chrysanthemum* petal cDNA clone with sequence similarity to the *Petunia* 3'-hydroxylase

- The cDNA insert from pCGP619 was used to screen cDNA library #3 for related  
 sequences. Using the hybridization and washing conditions described in the  
 20 Materials and Methods, 64 hybridizing clones were detected. Twelve of these  
 clones also hybridized to the insert from pCGP854. Sequence analysis of a  
 putative full-length clone that hybridized to both the pCGP619 and pCGP854  
 probes revealed that it included an identical sequence to that of the PCR product  
 sequence shown in Figure 11 and therefore encodes a putative chrysanthemum 3'-  
 25 hydroxylase.

#### Expression of a *Chrysanthemum* petal cDNA clone in yeast

- The petal cDNA clone can be ligated in a sense orientation behind the  
 glyceraldehyde-3-phosphate dehydrogenase promoter in the yeast vector  
 30 pYHCC101. The resulting construct is then transformed into the yeast strain G-  
 1315 (Ashikari *et al.*, 1989). Activity of the 3'-hydroxylase can be detected in  
 extracts of G-1315 plus construct, but not in extracts of non-transgenic yeast. From

SUBSTITUTE SHEET
------------------

- 37 -

this result it can be concluded that the cDNA insert encodes a 3'-hydroxylase.

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described.

- 5 It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

10

SUBSTITUTE SHEET
------------------

2/34




FIGURE 1A

SUBSTITUTE SHEET

3/34





FIGURE 1B

SUBSTITUTE SHEET



SUBSTITUTE SHEET

FIGURE 2A

5/34

pCGP 142

FIGURE 2B

```

      F   S   S   I   R   N   D   E   I   S   S   L
      TTT AGT TCA ATT CGG AAT GAT GAG ATT TCG AGT CTC

      I   S   S   I   H   S   M   N   G   S   V   V
      ATT TCA TCA ATT CAT TCC ATG AAC GGT TCT GTT GTC

      N   M   T   Q   K   I   L   C   F   T   N   S
      AAC ATG ACA CAA AAG ATT CTT TGT TTT ACA AAC TCT

      V   T   C   R   T   A   F   G   K   V   Y   K
      GTG ACT TGT AGA ACA GCT TTC GGG AAA GTA TAC AAA

      N   Q   N   E   L   I   N   L   M   R   E   V
      AAT CAA AAT GAA TTG ATA AAC TTG ATG AGG GAA GTA

      L   E   L   V   G   G   F   D   -----
      CTG GAA TTA GTA GGA GGA TTT GAT -----

      F   E   N   S   P   V   E   F   I   G   N   H
      TTT GAA AAT TCT CCG GTT GAG TTT ATT GGA AAT CAC

      F   E   L   V   P   F   G   A   G   K   R   I
      TTT GAG CTT GTT CCG TTT GGT GCA GGA AAA AGG ATT

      C   P   G   M   Q   F   G   L   A   N   I   R
      TGT CCA GGA ATG CAA TTT GGT TTA GCT AAT ATT AGA

      H   P   L   A   R   F   L   Y   H   F   N   W
      CAT CCT TTG GCT CGA TTC CTC TAC CAT TTT AAC TGG

      A   L   P   Y   E   T   N   P   E   D   L   D
      GCG CTT CCA TAT GAA ACT AAT CCT GAA GAT TTA GAT

      S   L   K   N   M   D
      AGT CTG AAA AAT ATG GAT TAA GTGCAGCAAAGAGAAAGA
      TCTATACTTAATTGCCGTAGATCACAAAGAAGGTGATATATAAATTC
      TGATGTTCTGCTTTAAATGGTGAAAGTCATACTCTACACAATGCTTC
      ATCTCCTTAATTTGAGTTTGGTGTACATTTGTGTCTCCCTTTTAGCT
      TTGAATTTACCTTGAAAAATGATCACATTTTCTTTTCTGTTACTC
      CAATTAAGATATATGTTGTGGTTGGTCAATTATGCCATATTTATCAA
      AAGATCAAATCAATTCCCTCGTTGATAAGTATAGATTATAAAACTGA
      TTAATGAATCAAAAAAAAAAAAAAAAAA

```

SUBSTITUTE SHEET



6/34

FIGURE 2C

FIGURE 2D

FIGURE 2E

SUBSTITUTE SHEET

7/34

pCGP147

FIGURE 2C

Q F F N L V S F L L I V F S L  
TGCAATTTTCAACTTGGTTTCCTTCTCCTTATTGTATTTTCCCTC  
10 20 30 40

→  
I S L R K W K K S N C Q T K K L  
ATTCATTAAGAAAATGGAAGAAATCCAATTGTCAAACCAAAAATTG  
58 68 78 88

P P G P W K V P F L G S L L H M  
CCTCCAGGCCCATGGAAAGTACCTTTTCTTGGAAGCTTGCTTCATATG  
106 116 126 136

V G G L P H H V L R D L A K K Y  
GTAGGTGGACTTCCACACCATGTCCTTAGAGATTAGCCAAAAAATAT  
154 164 174 184

G P I M H L Q L G K I S A V V V  
GGACCAATTATGCACCTTCAACTAGGTAAAATTTCTGCCGTTGTAGTT  
202 212 222 232

T S P E M A R K V L K T H D L A  
ACTTCTCCTGAGATGGCAAGAAAAGTACTAAAACTCATGACCTTGCA  
250 260 270 280

F A Y R P K L L G I E I V C Y N  
TTTGCATATAGGCCTAAACTTCTAGGCATTGAGATTGTCTGCTATAAT  
298 308 318 328

S S D I A F S P Y G D Y W R Q M  
AGTTCAGACATTGCCTTTTCCCCGTATGGTGATTACTGGAGGCAAATG  
346 356 366 376

R K I C V L E V L S A K N V R S  
CGTAAAATTTGTGTATTGGAAGTGCTTAGTGCCAAAATGTCCGGTCA  
394 404 414 424

F N S I R R D E I L L M I D F L  
TTTAACTCGATTAGACGAGATGAAATACTTCTTATGATCGATTTTGTG  
442 452 462 472

R S S S G K P V N I T E R I F S  
CGATCATCTTCTGGTAAGCCAGTTAATAACAGAAAGGATCTTTTCA  
490 500 510 520

SUBSTITUTE SHEET

8/34

FIGURE 2D

F T S S M I C R S V F G K R I K  
TTCACAAGCTCTATGATTTGTAGATCAGTATTTGGGAAAAGAATAAAG  
538 548 558 568

E K D E C I R H V K K M T G L I  
GAGAAAGACGAATGTATACGACATGTGAAAAAATGACAGGCTTAATA  
586 596 606 616

D G F D V A D I F P S L R F L H  
GATGGGTTCGATGTGGCTGACATATTCCTTCGTTGAGGTTTCTTCAT  
634 644 654 664

V L I G M K G K I M D V H R K V  
GTACTAATCGGTATGAAGGGTAAAATTATGGATGTTTCATCGTAAGGTA  
682 692 702 712

D A I V E E V M N E H K E T L R  
GATGCTATTGTTGAGGAAGTCATGAATGAGCACAAAGAACTCTTCGA  
730 740 750 760

T G K T N G E V G G E D L I D V  
ACTGGCAAGACCAATGGTGAAGTGGGAGGAGAAGATTTAATTGATGTA  
778 788 798 808

L L R L K E E G D L Q L P I T N  
TTGCTAAGACTTAAGGAAGAGGGAGACCTTCAACTTCCAATCACAAAT  
826 836 846 856

D N I K A I F N D M F A A G T E  
GACAACATCAAAGCCATTTTAAATGACATGTTTGCTGCGGGAACAGAA  
874 884 894 904

T S S T T I N W A M V E L M K N  
ACTTCATCAACAATAACTGGGCCATGGTAGAACTGATGAAAAAT  
922 932 942 952

P S V F A K A Q A E V R E V F K  
CCAAGTGTATTCGCGAAAGCTCAAGCAGAGGTAAGAGAAGTCTTCAA  
970 980 990 1000

G K E T F D E D D I E E L N Y L  
GGGAAAGAACTTTCGATGAAGATGATATCGAGGAGCTGAATTACCTT  
1018 1028 1038 1048

K L V I R E T L R L H P P L P L  
AAGTTAGTCATTAGAGAACTTTAAGACTCCACCCTCCACTTCCACTT  
1066 1076 1086 1096

**SUBSTITUTE SHEET**

9/34

L L P R E C R R E T E I N G Y T  
TTGCTTCCAAGAGAATGTCGGAGAGAAACAGAAATAAATGGCTACACT  
1114 1124 1134 1144

I P L N T K V I V N V W A I G R  
ATTCCTTTAAATACCAAAGTCATAGTTAATGTTTGGGCTATTGGAAGA  
1162 1172 1182 1192

D P K Y W D D A E S F K P E R F  
GATCCAAAATATTGGGATGATGCAGAAAGCTTTAAGCCTGAGAGATTT  
1210 1220 1230 1240

E H N S L N F A G N N F E Y L P  
GAACATAACTCTTTGAATTTTGCTGGCAATAATTTTGAATATCTTCCT  
1258 1268 1278 1288

F G S G R R I C P G I S F G L A  
TTTGGTAGTGGAAGGAGGATTTGCCCCGGAATATCATTGTTTAGCT  
1306 1316 1326 1336

N V Y H P L A Q L L Y H F D W R  
AATGTTTATCATCCATTGGCTCAATTGTTGTATCATTTTCGATTGGAGA  
1354 1364 1374 1384

L P T G V D P N D F E L T S \*  
CTTCCTACTGGGGTCGACCCAAATGACTTTGAATTGACTAGTTAGCTG  
1402 1412 1422 1432

GAGTAACTACTGGTAGGAAAAGAGACCTTTACTTGATTTTCACTCCTT  
1450 1460 1470 1480

ATTCACCTTCTCTAAAGTGATTAAATGG-GCAAATTTTAATTTGAAAT  
1498 1508 1518 1528

AATACTTTTTCTTGTTTACATTTCTCTCCCATTTGTTGTATTTTCATTTA  
1546 1556 1566 1576

CCTATTGTTGTACTTCTTTCTTTTGTGATGTCTTAGGTTTTACCTAT  
1594 1604 1614 1624

TTCTATGCATTTGTATTTAAAAA  
1642 1652 1662

FIGURE 2E

SUBSTITUTE SHEET

10/34

FIGURE 2F

## pCGP158

Gly Met Met Lys Gln Gly Asp Phe Leu Asp Val Leu  
GGG ATG ATG AAG CAA GGA GAT TTC TTG GAT GTA CTT

Leu Asp Gln Cys Asp Glu Glu Gly Ser Gly Phe Asp  
CTT GAT CAA TGT GAT GAA GAA GGG TCT GGA TTT GAT

Arg Gln Thr Ile Lys Pro Leu Ile Leu Asp Leu Phe  
CGC CAA ACT ATC AAG CCT CTC ATC CTG GAT TTA TTC

Ile Ala Gly Ser Asp Thr Ser Ala Ile Thr Thr Glu  
ATT GCT GGA AGT GAT ACA TCT GCC ATA ACA ACA GAA

Trp Ala Met Ala Glu Leu Leu Arg Lys Pro Gln Glu  
TGG GCA ATG GCA GAA CTA CTT CGA AAA CCT CAA GAA

Phe Val Asn Ala Trp Ala Ile Gly Arg Asp Pro Lys  
TTT GTG AAT GCA TGG GCA ATT GGA AGA GAT CCA AAA

Tyr Trp Glu Lys Pro Leu Glu Phe Met Pro Glu Arg  
TAC TGG GAA AAA CCA CTG GAG TTT ATG CCT GAA AGA

Phe Leu Lys Cys Ser Leu Asp Tyr Lys Gly Arg ---  
TTC TTG AAG TGT AGT TTG GAT TAC AAA GGT AGG G--

Phe Glu Tyr Ile Pro Phe Gly Ala Gly Arg Arg Ile  
TTT GAG TAT ATA CCA TTT GGC GCA GGT CGA AGA ATT

Cys Pro Gly Met Pro His Cys Asn Lys Asp Gly Glu  
TGT CCT GGA ATG CCA CAT TGC AAT AAG GAT GGT GAA

Phe Asp Ala Gly Phe Asp Tyr Ser Pro Phe Ser Trp  
TTT GAT GCT GGC TTC GAT TAT TCA CCA TTT AGT TGG

Glu Leu Pro --- Gly Met Ala Pro Lys --- Leu Asn  
GAA TTA CCT -AA GGA ATG GCA CCA AAG -AT TTG AAC

Met Glu Glu Gln Phe Gly Val Thr Leu Arg Lys Ala  
ATG GAG GAA CAG TTT GGA GTT ACC TTG AGG AAG GCT

Ile Pro Leu Ile Ala Ile Pro Ser Met Glu Glu Lys  
ATT CCC CTT ATT GCC ATT CCC AGT ATG GAA GAA AAG

Val Ile Phe

GTC ATA TTT TAG CCCAAAAGCTATGCATTTTGTGTGTATGTTT

SUBSTITUTE SHEET

11/34

pCGP 160

FIGURE 2G

K Q I N A L L V E I F G  
 AAA CAG ATC AAT GCA TTG CTT GTG GAA ATA TTT GGA  
 ----->

A G T E S T T A T S Q W  
 GCT GGT ACA GAA TCT ACA ACT GCT ACA AGC CAA TGG

M L V E L L R N R Q A L  
 ATG CTT GTA GAA CTC CTT AGA AAT CGA CAA GCC TTG

----- P K D T Q V M V N  
 -----CCC AAA GAC ACT CAA GTT ATG GTA AAC

E W A I A Y D P K I W G  
 GAG TGG GCG ATT GCG TAT GAT CCT AAG ATT TGG GGC

S F K P Q R F I D S K I  
 AGC TTC AAA CCC GAA AGG TTT ATC GAT TCA AAA ATA

D P L D H K G Q N F E Y  
 GAT CCT TTG GAC CAC AAA GGG CAA AAT TTT GAA TAT

F P F G S G R R I C A G  
 TTT CCT TTT GGT TCT GGA AGG AGA ATT TGT GCT GGA

E P L A S R V I P L A V  
 GAA CCT TTG GCT TCT AGG GTT ATT CCC TTA GCT GTT

A S M I H K F -----  
 GCT TCT ATG ATC CAT AAG TTT -----GATATCACTAT  
 <-----

GTTAGAAGATCCACTCTCATTCCTAAGTTGAGAAGAGTGAGGAA  
 ATTAAAAGAAGCAGAAGATATGTTACTATAAAAACTCGTTATATATA  
 TATATATTGCTGTATCTATATATGTGTGAATGATCTGCTGCTCATGT  
 TGTGTTTTGTTGTTTGTGTACTATAGGTCATACCTAAGTTGATGAAA  
 TGTCTCTGAGAATATATACTCCTTATATAATAGGAGTAATTTACCGA  
 TAATTAATATTCCTGCGACAAAAAAAAAAAAAAAAAAAA

SUBSTITUTE SHEET

12/34

## pCGP454



-	R	E	S	M	E	D	V	R	L	L	G
CT	CGA	GAA	TCA	ATG	GAA	GAT	GTA	AGA	TTA	CTA	GGC
											
Y	H	I	P	A	K	T	R	L	F	I	N
TAT	CAC	ATA	CCT	GCT	AAA	ACG	AGA	CTC	TTT	ATC	AAT
A	W	T	M	G	R	D	P	L	T	W	E
GCT	TGG	ACA	ATG	GGG	AGA	GAC	CCA	CTA	ACA	TGG	GAA
N	P	E	E	Y	Q	P	E	R	F	L	N
AAT	CCA	GAA	GAG	TAT	CAG	CCA	GAG	AGA	TTC	TTG	AAT
R	D	T	D	V	K	G	V	N	F	E	F
AGA	GAT	ACT	GAT	GTC	AAA	GGA	GTA	AAC	TTT	GAG	TTC
I	P	F	G	A	G	R	S				
ATT	CCC	TTT	GGC	GCC	GGC	AGA	AGC				
											

FIGURE 2H

SUBSTITUTE SHEET



13/34

FIGURE 3A

FIGURE 3B

FIGURE 3C

FIGURE 3D

SUBSTITUTE SHEET

14/34

FIGURE 3A

pCGP 602

CTTTCTACTAGCTACTTCGTTATATATATGTAAAATTGTGACTTT  
10 20 30 40

GAAAATCATTTTAAATTATCATAAGGTTTCATTTTATCTTGATCAAA  
55 65 75 85

ATATTTACTTCGGCCATATACGTTTTCTTTAGTCATGATGCTAC  
100 110 120 130

L T E L G A A T S I F L I A H  
TTACTGAGCTTGGTGCAGCAACTTCAATCTTTCTAATAGCACACA  
145 155 165 175

I I I S T L I S K T T G R H L  
TAATCATTTCAACTCTTATTTCAAAAACCTACCGGCCGCATCTAC  
190 200 210 220

P P G P R G W P V I G A L P L  
CGCCGGGGCCAAGAGGGTGGCCGGTGATCGGAGCACTTCCACTTT  
235 245 255 265

L G A M P H V S L A K M A K K  
TAGGAGCCATGCCACATGTTTCCTTAGCTAAAATGGCAAAAAAAT  
280 290 300 310

Y G A I M Y L K V G T C G M A  
ATGGAGCAATCATGTATCTCAAAGTTGGAACATGTGGCATGGCAG  
325 335 345 355

V A S T P D A A K A F L K T L  
TTGCTTCTACCCCTGATGCTGCTAAAGCATTCTTGAAAACACTTG  
370 380 390 400

D I N F S N R P P N A G A T H  
ATATCAACTTCTCCAATCGTCCACCTAATGCAGGTGCCACTCACT  
415 425 435 445

L A Y N A Q D M V F A H Y G P  
TAGCTTATAATGCTCAAGACATGGTTTTTGCACATTATGGACCAC  
460 470 480 490

R W K L L R K L S N L H M L G  
GATGGAAGTTGCTAAGGAAATTAAGCAACTTGCATATGCTAGGGG  
505 515 525 535

SUBSTITUTE SHEET

15/34

FIGURE 3B

G K A L E N W A N V R A N E L  
GAAAAGCCTTAGAGAATTGGGCAAATGTTTCGTGCCAATGAGCTAG  
550 560 570 580

G H M L K S M S D M S R E G Q  
GGCACATGCTAAAATCAATGTCCGATATGAGTCGAGAGGGCCAGA  
595 605 615 625

R V V V A E M L T F A M A N M  
GGGTTGTGGTGGCGGAGATGTTGACATTTGCCATGGCCAATATGA  
640 650 660 670

I G Q V M L S K R V F V D K G  
TCGGACAAGTGATGCTAAGCAAAGAGTATTTGTAGATAAAGGTG  
685 695 705 715

V E V N E F K D M V V E L M T  
TTGAGGTAAATGAATTTAAGGACATGGTTGTAGAGTTAATGACAA  
730 740 750 760

I A G Y F N I G D F I P C L A  
TAGCAGGGTATTTCAACATTGGTGATTTTATTCCTTGTTTAGCTT  
775 785 795 805

W M D L Q G I E K R M K R L H  
GGATGGATTTACAAGGGATAGAAAAACGAATGAAACGTTTACATA  
820 830 840 850

K K F D A L L T K M F D E H K  
AGAAGTTTGATGCTTTATTGACAAAGATGTTTGATGAACACAAAG  
865 875 885 895

A T T Y E R K G K P D F L D V  
CAACTACCTATGAACGTAAGGGGAAACCAGATTTTCTTGATGTTG  
910 920 930 940

V M E N G D N S E G E R L S T  
TTATGGAAAATGGGGACAATTCTGAAGGAGAAAGACTCAGTACAA  
955 965 975 985

T N I K A L L L N L F T A G T  
CCAACATCAAAGCACTTTTGCTGAATTTGTTTCACAGCTGGTACGG  
1000 1010 1020 1030

**SUBSTITUTE SHEET**

16/34

FIGURE 3C

D T S S S A I E W A L A E M M  
ACACTTCTTCTAGTGCAATAGAATGGGCACTTGCAGAAATGATGA  
1045 1055 1065 1075

K N P A I L K K A Q A E M D Q  
AGAACCCTGCCATTTTGA AAAAAGCACAAGCAGAAATGGATCAAG  
1090 1100 1110 1120

V I G R N R R L L E S D I P N  
TCATTGGAAGAAATAGGCGTTTACTCGAATCCGATATCCCAAATC  
1135 1145 1155 1165

L P Y L R A I C K E T F R K H  
TCCCTTACCTCCGAGCAATTTGCAAAGAAACATTTTCGAAAACACC  
1180 1190 1200 1210

P S T P L N L P R I S N E P C  
CTTCTACACCATTAATCTTCCTAGGATCTCGAACGAACCATGCA  
1225 1235 1245 1255

I V D G Y Y I P K N T R L S V  
TAGTCGATGGTTATTACATACCAAAAAACACTAGGCTTAGTGTTA  
1270 1280 1290 1300

N I W A I G R D P Q V W E N P  
ACATATGGGCAATTGGAAGAGATCCCCAAGTTTGGGAAAATCCAC  
1315 1325 1335 1345

L E F N P E R F L S G R N S K  
TAGAGTTTAATCCCGAAAGATTCTTGAGTGGAAGAAACTCCAAGA  
1360 1370 1380 1390

I D P R G N D F E L I P F G A  
TTGATCCTCGAGGGAACGATTTTGAATTGATACCATTTGGTGCTG  
1405 1415 1425 1435

G R R I C A G T R M G I V M V  
GACGAAGAATTTGTGCAGGAACAAGAATGGGAATTGTAATGGTGG  
1450 1460 1470 1480

E Y I L G T L V H S F D W K L  
AATATATATTAGGAACTTTGGTTCATTCATTTGATTGGAAATTAC  
1495 1505 1515 1525

**SUBSTITUTE SHEET**

17/34

P S E V I E L N M E E A F G L  
CAAGTGAAGTTATTGAGTTGAATATGGAAGAAGCTTTTGGCTTAG  
1540 1550 1560 1570

A L Q K A V P L E A M V T P R  
CTTTGCAGAAAGCTGTCCCTCTTGAAGCTATGGTTACTCCAAGGT  
1585 1595 1605 1615

L Q L D V Y V P \*  
TACAATTGGATGTTTATGTACCATAGCTATAGATGTGTATTGTGC  
1630 1640 1650 1660

TATAATTGCGCATGTTGTTGGTTGTAGCATGAGATATTAAAAGGA  
1675 1685 1695 1705

GTACATGAAGCGCATTGCATGAGTTTAACTTGTAGCTCCTTAATA  
1720 1730 1740 1750

TTTtaggtatttttcaattaataagttcttgttggttgggtaaaa  
1765 1775 1785 1795

AAAAAAAAAAAA  
1810

FIGURE 3D

SUBSTITUTE SHEET
------------------

FIGURE 4A

## 1) pCGP161

CCAGACACCCACAAACTTCCATACCTTCAGGCTGTGATCAAGGAGACTCT  
TCGTCTCCGGATGGCAATTCCTCTATTAGTCCCACACATG-----  
-----AAACTTTACAGAAAACGTTTCATCTTTTT  
ATGTCATATCAAGTCTTCTTGGACTGGTTCGTTATTACACCTACCTATCT  
GAATGTATTTTT

## 2) pCGP162

ACGAACATGGGAAAATCCAGAAGAGTATCAGCCAGAGAGATTCTTGAATA  
GTGATATTGATGTCAAAGGACTAAACTTTGAGTTGATTCC-----  
---ATGGCTAGTAGCTACTTCTTTCATGATATCTGTAATAAGTGTAGTGC  
TCGACTCCTTCAGGCGAGTTGTGTGTTTAATTTCTCCAGTATC

## 3) pCGP163

AAGTTCTTTCCATCAGTTATCAAACAAACCATGAGGCTGCATCCCCCTCT  
CCCTTTATTACTATTAAGGGAAAGCAAGGAATCTTGTGAA-----  
-----GATAGGGAGCGGTTTACTCCCTTCGTGGCCTTACCATTACACT  
ACAATGAATGGGCTTGGAAATAGTCTCAGATGTTTTTAAAGAAAAC

## 4) pCGP165

GTGATTTTCCAAAAGAATCTCACTTGCTGCAGATGTCCTATGTTCAAGCC  
TGTGTGAAGGAAACTCTTAGGTTGCATCCTCCGGCGCCAT-----  
-----TATTTATTGAAGTTGAGAACTTATGTATGAAAGTGTACATACAGA  
ACTACTGCCCATGTGGTGTGTTTTAGTACTTCTTTTTTTTTGGGT

## 5) pCGP166

ATGTCCTATGTTCAAGCCTGTGTGCCGGAAACTCTTAGGTTGCATCCTCC  
GGCGCCATTGCTACTTCCACATGCGTGCAATCGAAACATG-----  
-----TCCCCCTGGATTTGTACACTAGATACAAGACTT  
AGCGGTCCTGGTGTAAATCTCAATTCTCATGTGGTTATAAACAGAAGTTCT  
TCTGGTG

## 6) pCGP167

GAAACATTATCAATGAACATGTTAAGAATCGAGCACTCGGAAGCAAGGGA  
AATGGTGCGTTTGGAGGTGAAGATTTGGTTGATGTTTTAC-----  
-----GGTTGGGGTAAATTGGGGCCCCCCTTTTAAGGCTTTGGAATTT  
CCACCTGGAAAAATGGACCCCATTTTCCTTTTCCTGTACCTCCAATT

SUBSTITUTE SHEET
------------------

## 7) pCGP168

AAAAC TGCAA ACTAGCGATAACGCTGATGTTCTTGATGTGTTGTTGCATA  
CTAGCGAGGAAGATCCAGAGGCAATCGACAGAATTCACAT-----

## 8) pCGP169

CAGTACACTCTTTGTGTTTCATCATATCTCTTCACATTGCTCACAAGCTCG  
ACCATGGCCGTCGGTAAGAACAAGAGGATTTCCAAAGGCA-----  
-----AATACCACATTCTGATGATTCACCTTGATATATGTGTACCTTTATG  
TCATTTAATGGCACAACAATTCTGGGGACTTAGGTTCAAAGAAGC

## 9) pCGP171

CTGTAGGGTTACCGTTCATTGGAAATTTGCATCAATATGATACTTTAAAG  
CCGCATATCTACTTCTGGAAACTTTCTAGGAAGTATGGAA-----  
-----TACTTTCGGTTTTGAATTATGTATACATATATAAAACAAATGTGA  
AATGTATACATATAATAAAATTGCTCTCATGATATACTTCTCTAT

## 10) pCGP173

TTCTGGAAATGTTTCTAGCTGGTACAGAGACATCTAGCAGCACAACAGAG  
TGGGCACTAACTGAACTCCTTCGAAACCCAGAAACAATGG-----  
-----ACAATTCTTACGCTGAATTTGTTGTTTCGCCCTTTTATTTTCAGTT  
TGATTGTATCCAAAGGATGTCGAATGAAATCATACTCTTTACCT

FIGURE 4B

SUBSTITUTE SHEET
------------------



20/34

FIGURE 5A

FIGURE 5B

FIGURE 5C

FIGURE 5D

SUBSTITUTE SHEET

21/34

FIGURE 5A

CCGTTGCTGTCGAGAAAACAGAAAGAAGAGAAAA

35

ATG GAC TAC GTG AAT ATT TTG CTG GGA CTG TTT TTC ACT  
Met Asp Tyr Val Asn Ile Leu Leu Gly Leu Phe Phe Thr

TGG TTC TTG GTG AAT GGA CTC ATG TCA CTT CGA AGA AGA  
Trp Phe Leu Val Asn Gly Leu Met Ser Leu Arg Arg Arg

113

AAA ATC TCT AAG AAA CTT CCA CCA GGT CCA TTT CCT TTG  
Lys Ile Ser Lys Lys Leu Pro Pro Gly Pro Phe Pro Leu

CCT ATC ATC GGA AAT CTT CAC TTA CTT GGT AAT CAT CCT  
Pro Ile Ile Gly Asn Leu His Leu Leu Gly Asn His Pro

191

CAC AAA TCA CTT GCT CAA CTT GCA AAA ATT CAT GGT CCT  
His Lys Ser Leu Ala Gln Leu Ala Lys Ile His Gly Pro

ATT ATG AAT CTC AAA TTA GGC CAA CTA AAC ACA GTG GTC  
Ile Met Asn Leu Lys Leu Gly Gln Leu Asn Thr Val Val

269

ATT TCA TCA TCA GTC GTG GCA AGA GAA GTC TTG CAA AAA  
Ile Ser Ser Ser Val Val Ala Arg Glu Val Leu Gln Lys

CAA GAC TTA ACA TTT TCC AAT AGG TTT GTC CCG GAC GTA  
Gln Asp Leu Thr Phe Ser Asn Arg Phe Val Pro Asp Val

347

GTC CAT GTC CGA AAT CAC TCC GAT TTT TCT GTT GTT TGG  
Val His Val Arg Asn His Ser Asp Phe Ser Val Val Trp

TTA CCA GTC AAT TCT CGA TGG AAA ACG CTT CGC AAA ATC  
Leu Pro Val Asn Ser Arg Trp Lys Thr Leu Arg Lys Ile

**SUBSTITUTE SHEET**

22/34

FIGURE 5B

425

ATG AAC TCT AGC ATC TTT TCT GGT AAC AAG CTT GAT GGT  
Met Asn Ser Ser Ile Phe Ser Gly Asn Lys Leu Asp Gly

AAT CAA CAT CTG AGG TCT AAA AAG GTC CAA GAG TTA ATT  
Asn Gln His Leu Arg Ser Lys Lys Val Gln Glu Leu Ile

503

GAT TAT TGT CAA AAG TGT GCC AAG AAT GGC GAA GCA GTG  
Asp Tyr Cys Gln Lys Cys Ala Lys Asn Gly Glu Ala Val

GAT ATA GGA AGA GCA ACT TTT GGA ACT ACT TTG AAT TTG  
Asp Ile Gly Arg Ala Thr Phe Gly Thr Thr Leu Asn Leu

581

CTA TCC AAC ACC ATT TTC TCT AAA GAT TTG ACT AAT CCG  
Leu Ser Asn Thr Ile Phe Ser Lys Asp Leu Thr Asn Pro

TTT TCT GAT TCT GCT AAA GAG TTT AAG GAA TTG GTT TGG  
Phe Ser Asp Ser Ala Lys Glu Phe Lys Glu Leu Val Trp

659

AAC ATT ATG GTT GAG GCT GGA AAA CCC AAT TTG GTG GAC  
Asn Ile Met Val Glu Ala Gly Lys Pro Asn Leu Val Asp

TAC TTT CCT TTC CTT GAG AAA ATT GAT CCG CAA GGT ATA  
Tyr Phe Pro Phe Leu Glu Lys Ile Asp Pro Gln Gly Ile

737

AAG CGA CGC ATG ACT AAT AAT TTT ACT AAG TTT CTT GGC  
Lys Arg Arg Met Thr Asn Asn Phe Thr Lys Phe Leu Gly

CTT ATC AGC GGT TTG ATT GAT GAC CGG TTA AAG GAA AGG  
Leu Ile Ser Gly Leu Ile Asp Asp Arg Leu Lys Glu Arg

**SUBSTITUTE SHEET**

23/34

FIGURE 5C

815

AAT CTA AGG GAC AAT GCA AAT ATT GAT GTT TTA GAC GCC  
Asn Leu Arg Asp Asn Ala Asn Ile Asp Val Leu Asp Ala

CTT CTC AAC ATT AGC CAA GAG AAC CCA GAA GAG ATT GAC  
Leu Leu Asn Ile Ser Gln Glu Asn Pro Glu Glu Ile Asp

893

primer191

AGG AAT CAA ATC GAG CAG TTG TGT CTG GAC TTG TTT GCA  
Arg Asn Gln Ile Glu Gln Leu Cys Leu Asp Leu Phe Ala

primer190

GCA GGG ACT GAT ACT ACA TCG AAT ACC TTG GAG TGG GCA  
Ala Gly Thr Asp Thr Thr Ser Asn Thr Leu Glu Trp Ala

971

ATG GCA GAA CTA CTT CAG AAT CCA CAC ACA TTG CAG AAA  
Met Ala Glu Leu Leu Gln Asn Pro His Thr Leu Gln Lys

GCA CAA GAA GAA CTT GCA CAA GTC ATT GGT AAA GGC AAA  
Ala Gln Glu Glu Leu Ala Gln Val Ile Gly Lys Gly Lys

1049

CAA GTA GAA GAA GCA GAT GTT GGA CGA CTA CCT TAC TTG  
Gln Val Glu Glu Ala Asp Val Gly Arg Leu Pro Tyr Leu

CGA TGC ATA GTG AAA GAA ACC TTA CGA ATA CAC CCA GCG  
Arg Cys Ile Val Lys Glu Thr Leu Arg Ile His Pro Ala

1127

GCT CCT CTC TTA ATT CCA CGT AAA GTG GAG GAA GAC GTT  
Ala Pro Leu Leu Ile Pro Arg Lys Val Glu Glu Asp Val

GAG TTG TCT ACC TAT ATT ATT CCA AAG GAT TCA CAA GTT  
Glu Leu Ser Thr Tyr Ile Ile Pro Lys Asp Ser Gln Val

SUBSTITUTE SHEET
------------------

24/34

FIGURE 5D

1205

CTA GTG AAC GTA TGG GCA ATT GGA CGC AAC TCT GAT CTA  
Leu Val Asn Val Trp Ala Ile Gly Arg Asn Ser Asp Leu

TGG GAA AAT CCT TTG GTC TTT AAG CCA GAA AGG TTT TGG  
Trp Glu Asn Pro Leu Val Phe Lys Pro Glu Arg Phe Trp

1283

GAG TCA GAA ATA GAT ATC CGA GGT CGA GAT TTT GAA CTC  
Glu Ser Glu Ile Asp Ile Arg Gly Arg Asp Phe Glu Leu

ATT CCA TTT GGT GCT GGT CGA AGA ATT TGC CCT GGA TTG  
Ile Pro Phe Gly Ala Gly Arg Arg Ile Cys Pro Gly Leu

1361

CCT TTG GCT ATG AGG ATG ATT CCA GTA GCA CTA GGT TCA  
Pro Leu Ala Met Arg Met Ile Pro Val Ala Leu Gly Ser

TTG CTA AAC TCA TTT AAT TGG AAA CTA TAT GGT GGA ATT  
Leu Leu Asn Ser Phe Asn Trp Lys Leu Tyr Gly Gly Ile

1439

GCA CCT AAA GAT TTG GAC ATG CAG GAA AAG TTT GGC ATT  
Ala Pro Lys Asp Leu Asp Met Gln Glu Lys Phe Gly Ile

ACC TTG GCG AAA GCC CAA CCT CTG CTA GCT ATC CCA ACT  
Thr Leu Ala Lys Ala Gln Pro Leu Leu Ala Ile Pro Thr

1517

CCC CTG TAG CTATAGGGATAAATTAAGTTGAGGTTTTAAGTTACTAGT  
Pro Leu

AGATTCTATTGCAGCTATAGGATTTCTTTCACCATCACGTATGCTTTACCG  
TTGGATGATGGAAAGAAATATCTATAGCTTTGGGTTTGTTTAGTTTGCACA  
TAAAAATTGAATGAATGGAATACCATGGAGTTATAAGAAATAATAAGACTA  
TGATTCTTACCCTACTTGAACAATGACATGGCTATTTTCAC

**SUBSTITUTE SHEET**




FIGURE 6

SUBSTITUTE SHEET

26/34




FIGURE 7




27/34

FIGURE 8

## Sequence of pCGP635 insert

Leu Glu Trp Ala Met Ala Glu Ile Leu Arg His Pro Arg Val Cys Arg Lys Met Gln Asn  
 TTG GAG TGG GCA ATG GCC GAA ATC TTG AGG CAT CCC AGA GTT TGT AGA AAA ATG CAA AAT  
 3  
 Glu Ala Met Glu Ile Ala Asn Gly Lys Pro His Ile Thr Glu Ser Asp Leu Asp Lys Met  
 GAG GCG ATG GAG ATT GCT AAT GGC AAA CCA CAC ATC ACA GAA AGT GAT TTA GAT AAA ATG  
 63  
 His Tyr Leu Lys Ala Val Ile Lys Glu Thr Leu Arg Leu Leu Pro Pro Ile Pro Leu Leu  
 CAC TAC TTG AAA GCA GTG ATC AAA GAG ACA CTT CCG CTA CAT CCG CCA ATA CCA TTA CTC  
 123  
 Ser Pro Arg Glu Ser Thr Glu Asp Val Lys Ile Met Glu Ser Ser Asp Ile Glu Val Lys Lys  
 TCC CCT CGT GAA TCA ACT GAA GAT GTT AAG ATA ATG GAA TCT GAC ATA GAA GTC AAA AAA  
 183  
 Leu Trp Ser Leu Ser Met Leu Gly Gln Ser Glu Glu Thr Gln Gln Ser Gly Met Asn Gln  
 CTA TGG TCT TTA TCA ATG CTT GGG CAA TCG GAA GAG ACC CAG CAG CAG AGT GGG ATG AAC CAA  
 243  
 Glu Phe Arg Pro Glu Arg Phe Met Asn Ser Ser Val Asp Phe Lys Gly His Leu Phe Gln  
 GAG TTT CGA CCG GAG AGA TTC ATG AAT TCT TCT TCT GTG GAT TTC AAA GGT CAT CTC TTT CAA  
 303  
 Leu Leu Pro Phe Gly Ala Gly Arg Arg  
 TTA CTC CCC TTC GGA GCC GGC CGC AGA T  
 363

SUBSTITUTE SHEET



29/34

# Sequence of pCGP772 insert

Ala	Glu	Leu	Leu	Arg	Asn	Pro	Glu	Lys	Met		
<u>TG</u>	<u>GCG</u>	GAA	CTA	CTG	CGC	AAC	CCC	GAG	AAA	ATG	
		10			20			30			
Ala	Lys	Ala	Gln	Asp	Glu	Ile	Asp	Arg	Ile	Val	
GCA	AAA	GCA	CAA	GAC	GAA	ATA	GAC	CGA	ATA	GTA	
		40			50			60			
Gly	Asp	Lys	Asn	Lys	Ser	Phe	Gln	Glu	Thr	Asp	
GGC	GAC	AAG	AAC	AAA	TCG	TTC	CAA	GAG	ACA	GAC	
	70			80			90				
Ile	Ser	Lys	Leu	Pro	Tyr	Ile	Gln	Ala	Val	Val	
ATC	TCA	AAG	TTA	CCG	TAC	ATT	CAA	GCG	GTT	GTT	
100			110			120				130	
Lys	Glu	Thr	Leu	Arg	Leu	His	Pro	Pro	Gly	Pro	
AAA	GAA	ACA	TTA	AGG	CTA	CAC	CCG	CCT	GGA	CCG	
			140			150				160	
Phe	Leu	Ile	Pro	His	Lys	Ala	Glu	Lys	Asp	Val	
TTC	CTA	ATA	CCC	CAC	AAA	GCC	GAA	AAG	GAC	GTA	
		170			180			190			
Asn	Leu	Ser	Arg	Phe	Phe	Ile	Pro	Glu	Asp	Ala	
AAC	TTA	AGC	CGG	TTT	TTC	ATC	CCC	GAG	GAC	GCC	
	200			210			220				
Gln	Val	Trp	Val	Asn	Val	Trp	Ala	Ile	Gly	Arg	
CAA	GTG	TGG	GTC	AAT	GTA	TGG	GCC	ATT	GGT	CGT	
230			240			250				260	

FIGURE 9A


SUBSTITUTE SHEET

30/34

Asp	Pro	Ser	Val	Trp	Arg	Val	Pro	Leu	Thr	Leu
GAT	CCA	AGC	GTG	TGG	CGG	GTC	CCA	CTT	ACA	TTG
		270			280				290	
Cys	Pro	Glu	Arg	Phe	Leu	Glu	Asn	Asp	Ile	Asp
TGT	CCT	GAA	CGG	TTT	TTG	GAA	AAC	GAC	ATC	GAT
	300			310				320		
Phe	Lys	Gly	Thr	Asp	Phe	Glu	Leu	Ile	Pro	Phe
TTC	AAA	GGT	ACA	GAT	TTC	GAG	CTG	ATT	<u>CCC</u>	<u>TTT</u>
330			340				350			360
Gly	Ala	Gly	Arg	Ile						
<u>GGC</u>	<u>GCC</u>	<u>GGC</u>	<u>CGC</u>	<u>ATC</u>						
		370								

FIGURE 9B

SUBSTITUTE SHEET



## Sequence of pCGP773 insert

Met Ala Glu Leu Leu Arg Asn Pro Glu Lys Leu  
A ATG GCA GAG CTG CTC CGT AAC CCA GAA AAA CTG  
                   10                  20                  30

Lys Lys Ala Gln Val Glu Leu Gln Glu Ile Ile  
 AAG AAA GCA CAA GTA GAG CTT CAA GAA ATC ATC  
           40                  50                  60

Gly Arg Gly Asn Thr Leu Glu Glu Ser Asp Ile  
 GGC AGA GGA AAC ACA TTA GAG GAA TCT GAC ATC  
       70                  80                  90                  100

Ser Arg Leu Pro Tyr Leu Gln Ala Ile Ile Lys  
 AGT CGA TTG CCA TAT TTA CAG GCT ATC ATT AAG  
                   110                  120                  130

Glu Thr Phe Arg Leu His Pro Gly Leu Pro Leu  
 GAA ACA TTT CGG CTA CAC CCA GGA CTG CCA TTA  
           140                  150                  160

Leu Leu Pro Arg Lys Val Gly Ser Asp Val Gln  
 TTG CTA CCT AGG AAA GTT GGT TCA GAC GTT CAG  
       170                  180                  190

Leu Phe Gly Phe Thr Val Pro Lys Asn Ala Gln  
 CTC TTT GGG TTT ACA GTA CCC AAA AAT GCA CAA  
 200                  210                  220                  230

Val Ile Ile Asn Ala Trp Ala Ile Gly Arg Asp  
 GTC ATA ATC AAC GCC TGG GCA ATT GGG AGA GAC  
           240                  250                  260

### FIGURE 10 A

SUBSTITUTE SHEET
------------------

33/34

Pro	Asp	Cys	Trp	Gln	Lys	Pro	Asn	Ser	Phe	Glu
CCA	GAT	TGT	TGG	CAG	AAA	CCC	AAC	TCA	TTT	GAG
270			280			290				

Pro	Glu	Arg	Phe	Leu	Gly	Ser	Gln	Ile	Asp	Val
CCA	GAA	AGG	TTC	CTT	GGG	TCA	CAA	ATT	GAT	GTG
300		310			320			330		

Lys	Gly	Arg	Asp	Phe	Glu	Leu	Ile	Pro	Phe	Gly
AAG	GGT	CGT	GAT	TTT	GAG	CTA	ATT	<u>CCC</u>	<u>TTT</u>	<u>GGC</u>
340				350			360			

Ala	Gly	Arg	Ser	Ile	Cys	Ala
<u>GCC</u>	<u>GGC</u>	<u>CGC</u>	<u>AGC</u>	<u>ATC</u>	<u>TGT</u>	<u>GCC</u> G
370			380			

FIGURE 10 B

SUBSTITUTE SHEET



Partial sequence of pCGP854 insert

PRIMER 190 --->

TTG GAG TGG GCA ATG GCA GAA CTT CTA CGC AAC CCG CAC ACC ATG  
Leu Glu Trp Ala Met Ala Glu Leu Leu Arg Asn Pro His Thr Met  
1

GCC AAA GCA AAA GAG GAG CTT AAA GAC GTT ATC GGC AAA GAA AAA  
Ala Lys Ala Lys Glu Glu Leu Lys Asp Val Ile Gly Lys Glu Lys  
46

CTT GTA GAT GAA GCT GAC ATT TTC GAG ACT  
Leu Val Asp Glu Ala Asp Ile Phe Glu Thr  
91

SUBSTITUTE SHEET

FIGURE 11

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> Int. CL <sup>5</sup> C12N 15/53, 15/11, 9/02, C12Q 1/68, A01H 5/00  According to International Patent Classification (IPC) or to both national classification and IPC				
<b>B. FIELDS SEARCHED</b>  Minimum documentation searched (classification system followed by classification symbols) IPC C12N 15/53  Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched AU: C12N 15/53  Electronic data base consulted during the international search (name of data base, and where practicable, search terms used) DERWENT DATABASE; WPAT; KEYWORDS FLAVAN: OR PETUNIA DERWENT DATABASE; BIOT CHEMICAL ABSTRACTS; CASA; KEYWORDS HYDROLAS: AND (FLAVAN: OR PETUN:)				
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>				
<b>Category *</b>	<b>Citation of document, with indication, where appropriate, of the relevant passages</b>	<b>Relevant to Claim No.</b>		
X	The Journal of Biological Chemistry, volume 267, No. 8, issued March 15 1992, Bristch et al, "Molecular Cloning, Sequence Analysis, and In Vitro Expression of Flavanone 3B-Hydroxylase from Petunia hybrida" pp 5380-5387 Abstract, figure 3, page 5383, figure 5, page 5384, figure 8	1,2,4-6,14,18,22-25		
Y		8-16,19,20,27-41,43-50,52-54		
Y	AU,A,54123/90 (DNA PLANT TECHNOLOGY CORP) 18 October 1990 (18.10.90) Claims 12,17,22-27, page 7 line 11, page 13 line 26 to page 48 line 30	8-16,19,20,27-41,43-50,52-54		
<div style="display: flex; justify-content: space-between;"> <div> <input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C.         </div> <div> <input checked="" type="checkbox"/> See patent family annex.         </div> </div>				
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top;"> <b>* Special categories of cited documents :</b>  <b>"A"</b> document defining the general state of the art which is not considered to be of particular relevance  <b>"E"</b> earlier document but published on or after the international filing date  <b>"L"</b> document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  <b>"O"</b> document referring to an oral disclosure, use, exhibition or other means  <b>"P"</b> document published prior to the international filing date but later than the priority date claimed             </td> <td style="width: 50%; vertical-align: top;"> <b>"T"</b> later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  <b>"X"</b> document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  <b>"Y"</b> document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art  <b>"&amp;"</b> document member of the same patent family             </td> </tr> </table>			<b>* Special categories of cited documents :</b> <b>"A"</b> document defining the general state of the art which is not considered to be of particular relevance <b>"E"</b> earlier document but published on or after the international filing date <b>"L"</b> document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) <b>"O"</b> document referring to an oral disclosure, use, exhibition or other means <b>"P"</b> document published prior to the international filing date but later than the priority date claimed	<b>"T"</b> later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention <b>"X"</b> document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone <b>"Y"</b> document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art <b>"&amp;"</b> document member of the same patent family
<b>* Special categories of cited documents :</b> <b>"A"</b> document defining the general state of the art which is not considered to be of particular relevance <b>"E"</b> earlier document but published on or after the international filing date <b>"L"</b> document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) <b>"O"</b> document referring to an oral disclosure, use, exhibition or other means <b>"P"</b> document published prior to the international filing date but later than the priority date claimed	<b>"T"</b> later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention <b>"X"</b> document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone <b>"Y"</b> document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art <b>"&amp;"</b> document member of the same patent family			
Date of the actual completion of the international search 10 June 1993 (10.06.93)		Date of mailing of the international search report 29 JUNE 1993 (29.06.93)		
Name and mailing address of the ISA/AU  AUSTRALIAN PATENT OFFICE PO BOX 200 WODEN ACT 2606 AUSTRALIA  Facsimile No. 06 2853929		Authorized officer  R. OSBORNE  Telephone No. (06) 2832313		

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate of the relevant passages	Relevant to Claim No.
P,X	AU,A,19530/92 (INTERNATIONAL FLOWER DEVELOPMENTS) 21 January 1993 page 4 lines 12-17, claims 1,2,4,5,7-11,13,15-16,18-21,23-25,27-29	1-6,8-16,22-25,31-38,47-50,47-54

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member					
AU	54123/90	WO	9011682	EP	465572	WO	9012084
		US	5034323				
AU	19530/92	AU	22733/92	EP	522880	WO	9301290
END OF ANNEX							

## REFERENCES:

Ashikari, T., Kiuchi-Goto, N., Tanaka, Y., Shibano, Y., Amachi, T., and Yoshizumi, H. *Appl. Microbiol. Biotechnol.* 30: 515-520, 1989.

Aviv, H. and Leder, P., *Proc. Natl. Acad. Sci. USA* 69: 1408-1412, 1972.

Bethesda Research Laboratories. BRL pUC host: *E. coli* DH5a<sup>TM</sup> competent cells. *Bethesda Res. Lab. Focus.* 8(2): 9, 1986.

Bozak, K.R., Yu, H., Sirevag, R. and Christoffersen, R.E., *Proc. Natl. Acad. Sci. USA* 87: 3904-3908, 1990.

Bullock, W. O., Fernandez, J.M. and Short, J.M. *Biotechniques* 5: 376, 1987.

Comai, L., Moran, P. and Maslyar, D., *Plant Molecular Biology* 15: 373-381, 1990.

Ebel, J. and Hahlbrock, K., In *The Flavonoids: Advances in Research Since 1980*. Harborne, J.B. (Ed.), Academic Press, New York, USA, 641-679, 1988.

Forkmann, G. *Plant Breeding* 106: 1-26, 1991.

Garfinkel, D.J. and Nester, E.W. *J. Bacteriol.* 144:732-743, 1980.

Hahlbrock, K. and Grisebach, H. *Annu. Rev. Plant Physiol.* 30: 105-130, 1979.

Hanahan, D. *J. Mol. Biol.* 166: 557, 1983.

Holton, T.A. and Graham, M.W. *Nucleic Acids Research* 19: 1156, 1991.

Inoue, H., Nojima, H. and Okayama, H. *Gene* 96: 23-28, 1990.

Ito, H., Fukuda, Y., Murata, K. and Kimura, A. *J. Bacteriol.*, 153: 163-168, 1983.

Jefferson, R.A., Kavanagh, T.A. and Bevan, M.W. *EMBO J.* 6(13): 3901-3907, 1987.

Lazo, G.R., Pascal, A.S. and Ludwig, R.A. *Bio/technology* 9: 963-967, 1991.

McBride, K.E. and Summerfelt, K.R. *Plant Molecular Biology* 14: 269-276 1990.

Merrifield, J. *Am. Chem. Soc.* 85: 2149, 1964.

Murashige, T. and Skoog, F. *Physiol. Plant* 15: 73-97, 1962.

Norrander, J., Kemp, T. and Messing, J. *Gene* 26: 101, 1983.

Pearson, W.R. and Lipman, D.J. *Proc. Natl. Acad. Sci. USA* 85: 2444-2448, 1988.

Sambrook, J., Fritsch, E.F. and Maniatis, T. *Molecular Cloning: A Laboratory Manual* (2nd edition). Cold Spring Harbor Laboratory Press, USA, 1989.

Sanger, F., Nicklen, S. and Coulson, A. *Proc. Natl. Acad. Sci. USA* 74: 5463-5467, 1977.

Schenk, R.U. and Hilderbrandt, A.C. *Can. J. Bot.* 50: 199-204, 1972.

Schram, A.W., Jonsson, L.M.V. and Bennink, G.J.H. Biochemistry of flavonoid synthesis in *Petunia hybrida*. In: *Petunia* Sink, K.C. (Ed.) Springer-Verlag, Berlin, Germany pp 68-75, 1984.

- 40 -

Stafford, H.A. *Flavonoid Metabolism*. CRC Press, Inc. Boca Raton, Florida, USA, 1990.

Stotz, G. and Forkmann, G. *Z. Naturforsch* 37c: 19-23, 1982.

Tanaka, Y., Ashikari, T., Shibano, Y., Amachi, T., Yoshizumi, H. and Matsubara, H. *J. Biochem* 103: 954-961, 1988.

Turpen, T.H. and Griffith, O.M. *BioTechniques* 4: 11-15, 1986.

Wiering, H. and De Vlaming, P. Inheritance and Biochemistry of Pigments. In: *Petunia* Sink, K.C. (Ed.), Springer-Verlag, Berlin, Germany pp 49-65, 1984.

Yanisch-Perron, C., Vieira, J. and Messing, J. *Gene* 33: 103, 1985.

SUBSTITUTE SHEET
------------------

**CLAIMS:**

1. A nucleic acid isolate comprising a sequence of nucleotides encoding, or complementary to a sequence encoding, flavonoid 3'-hydroxylase enzyme or a functional derivative of the enzyme.
2. A nucleic acid isolate according to claim 1 wherein said nucleic acid is DNA or cDNA.
3. A nucleic acid isolate according to claim 1 wherein said nucleic acid is genomic DNA.
4. A nucleic acid isolate according to claim 1 or 2 or 3 wherein the enzyme is of petunia, carnation, chrysanthemum, rose, maize, snapdragon, tobacco, cornflower, pelargonium or morning glory origin.
5. A nucleic acid isolate according to claim 4 wherein the enzyme is of petunia, carnation, chrysanthemum or rose origin.
6. A nucleic acid isolate according to claim 4 wherein the enzyme is of petunia origin.
7. A nucleic acid isolate according to claim 1 having a nucleotide sequence comprising substantially all or part of the nucleotide sequence set forth in Figure 5 or having at least 40% similarity to one or more regions thereof.
8. A nucleic acid isolate according to any one of claims 1 to 7 when present in a transgenic plant.



9. A nucleic acid isolate according to claim 8 wherein the transgenic plant exhibits an altered level of flavonoid 3'-hydroxylase activity.
10. A nucleic acid isolate according to claim 9 wherein the altered level of flavonoid 3'-hydroxylase activity is a reduction in activity.
11. A nucleic acid isolate according to claims 8 or 9 wherein the transgenic plant is petunia, carnation, chrysanthemum, rose, snapdragon, tobacco, cornflower, pelargonium, lisianthus or morning glory.
12. A nucleic acid isolate according to claims 8 or 9 wherein the transgenic plant is petunia, carnation, chrysanthemum or rose.
13. A nucleic acid isolate according to claim 10 wherein the transgenic plant is a petunia.
14. A nucleic acid isolate according to any one of claims 1 to 13 contained in a vector.
15. A nucleic acid isolate according to claim 14 wherein the vector is a binary vector.
16. A nucleic acid isolate according to claim 14 wherein the vector is a viral vector.
17. A nucleic acid isolate according to claim 14 or 15 wherein the vector and nucleic acid isolate is pCGP809.
18. An oligonucleotide comprising a sequence of nucleotides capable of hybridizing to the nucleic acid isolate of claim 1.

19. An oligonucleotide according to claim 18 wherein the oligonucleotide is capable of hybridizing to the 5' region of the nucleic acid isolate according to claim 1.
20. An oligonucleotide according to claim 18 wherein the oligonucleotide is capable of hybridizing to the 3' region of the nucleic acid isolate according to claim 1.
21. An oligonucleotide according to any of claims 18, 19 and 20 selected from the list comprising:
- GCTAAAGAGTTTAAGGAA  
AAGAAACTTCCACCAGGTCCATT  
TTGGAGTGGGCAATGGC  
GGACTTGTTTGCAGCAGG  
CCATTTGGTGCTGGTCGAAGAATTGCCCTGG
22. A flavonoid 3'-hydroxylase, or a functional derivative thereof, encoded by the nucleic acid according to claim 1.
23. A flavonoid 3'-hydroxylase according to claim 22 wherein said enzyme is of petunia, carnation, chrysanthemum, rose, maize, snapdragon, tobacco, cornflower, pelargonium or morning glory origin.
24. A flavonoid 3'-hydroxylase according to claim 22 wherein said enzyme is of petunia, carnation, chrysanthemum or rose origin.
25. A flavonoid 3'-hydroxylase according to claim 23 wherein the enzyme is of petunia origin.
26. A flavonoid 3'-hydroxylase according to claim 23 or 24 or 25 having an amino acid sequence comprising substantially all or a part of the amino acid sequence set forth in Figure 5 or having at least 40% similarity to one or more regions thereof.

27. A flavonoid 3'-hydroxylase according to any one of claims 22 to 26 when produced or capable of being produced in a transgenic plant.
28. A flavonoid 3'-hydroxylase according to claim 27 when the transgenic plant is petunia, carnation, chrysanthemum, rose, snapdragon, tobacco, cornflower, pelargonium, lisianthus or morning glory.
29. A flavonoid 3'-hydroxylase according to claim 27 when the transgenic plant is petunia, carnation, chrysanthemum or rose.
30. A flavonoid 3'-hydroxylase according to claim 27 wherein the transgenic plant is a petunia.
31. A method for producing a transgenic plant capable of synthesizing a 3'-hydroxylase or active mutants or derivatives thereof, said method comprising stably transforming a cell of a suitable plant with the nucleic acid according to claim 1 or any one of claims 14 to 16 under conditions permitting the eventual expression of said nucleic acid, regenerating a transgenic plant from the cell and growing said transgenic plant for a time and under conditions sufficient to permit the expression of the nucleic acid.
32. A method according to claim 31 wherein the expression of the nucleic acid is developmentally regulated.
33. A method according to claim 32 wherein the enzyme is of petunia, carnation, chrysanthemum, rose, maize, snapdragon, tobacco, cornflower, pelargonium or morning glory origin.
34. A method according to claim 33 wherein the enzyme is of petunia, carnation, chrysanthemum or rose origin.

35. A method according to claim 34 wherein the enzyme is of petunia origin.
36. A method according to any one of claims 31 to 35 wherein the transgenic plant is petunia, carnation, chrysanthemum, rose, snapdragon, tobacco, cornflower, pelargonium, lisianthus or morning glory.
37. A method according to claim 36 wherein the transgenic plant is petunia, carnation, chrysanthemum or rose.
38. A method according to claim 36 wherein the transgenic plant is a petunia.
39. A method for producing a transgenic plant with reduced endogenous or existing flavonoid 3'-hydroxylase activity, said method comprising stably transforming a cell of a suitable plant with a nucleic acid molecule which comprises a sequence of nucleotides encoding or complementary to a sequence encoding said flavonoid 3'-hydroxylase, regenerating a transgenic plant from the cell and, where necessary, growing said transgenic plant under conditions sufficient to permit expression of the nucleic acid.
40. A method for producing a genetically modified plant with reduced endogenous or existing flavonoid 3'-hydroxylase activity, said method comprising altering the flavonoid 3'-hydroxylase gene through modification of the endogenous sequences via homologous recombination from an appropriately altered flavonoid 3'-hydroxylase gene or derivative or part thereof introduced into the plant cell and regenerating the genetically modified plant from the cell.
41. A method according to claim 39 wherein the expression of the nucleic acid molecule is developmentally regulated.

42. A method according to claim 39 wherein the nucleic acid molecule has a nucleotide sequence which is substantially complementary or at least 40% complementary to all or part of the nucleotide sequence set forth in Figure 5.
43. A method according to claims 39 or 40 wherein the transgenic plant or genetically altered plant is petunia, carnation, chrysanthemum, rose, snapdragon, tobacco, cornflower, pelargonium, lisianthus or morning glory.
44. A method according to claims 39 or 40 wherein the transgenic plant or genetically altered plant is petunia, carnation, chrysanthemum or rose.
45. A method according to claim 44 wherein the transgenic or genetically altered plant is a petunia.
46. A method according to claim 39 or 40 wherein the transgenic plant is produced by introducing the nucleic acid according to any one of claims 14 to 16.
47. A transgenic plant or progeny thereof carrying an introduced nucleic acid molecule comprising a nucleotide sequence encoding, or complementary to a sequence encoding, flavonoid 3'-hydroxylase enzyme, or a functional derivative thereof.
48. A transgenic plant according to claim 47 wherein the enzyme is of petunia, carnation, chrysanthemum, rose, maize, snapdragon, tobacco, cornflower, pelargonium or morning glory origin.
49. A transgenic plant according to claim 48 wherein the enzyme is of petunia, carnation, chrysanthemum or rose origin.

50. A transgenic plant according to claim 49 wherein the enzyme is of petunia origin.
51. A transgenic plant according to claim 48 or 49 or 50 wherein the enzyme has an amino acid sequence substantially as set forth in Figure 5 or having at least 40% similarity to one or more regions thereof.
52. A transgenic plant according to any one of claims 47 to 51 wherein said plant is petunia, carnation, chrysanthemum, rose, snapdragon, tobacco, cornflower, pelargonium, lisianthus or morning glory.
53. A transgenic plant according to claim 52 wherein said plant is petunia, carnation, chrysanthemum or rose.
54. A transgenic plant according to claim 53 wherein the transgenic plant is a petunia.

1/34

FIGURE 1A

FIGURE 1B

SUBSTITUTE SHEET